<SEC-DOCUMENT>0001628280-23-002037.txt : 20230202
<SEC-HEADER>0001628280-23-002037.hdr.sgml : 20230202
<ACCEPTANCE-DATETIME>20230202160204
ACCESSION NUMBER:		0001628280-23-002037
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20230202
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230202
DATE AS OF CHANGE:		20230202

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cardiff Oncology, Inc.
		CENTRAL INDEX KEY:			0001213037
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				272004382
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35558
		FILM NUMBER:		23580787

	BUSINESS ADDRESS:	
		STREET 1:		11055 FLINTKOTE AVENUE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858-952-7570

	MAIL ADDRESS:	
		STREET 1:		11055 FLINTKOTE AVENUE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Trovagene, Inc.
		DATE OF NAME CHANGE:	20130304

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TrovaGene Inc.
		DATE OF NAME CHANGE:	20110830

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XENOMICS INC
		DATE OF NAME CHANGE:	20040719
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>crdf-20230202.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:3c326e01-e1b2-4e6a-a928-18813257a8d6,g:6855d6d1-d8b6-4076-938e-4db32b3319c3,d:17bcf93b648e473897bd868e573b804b--><html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>crdf-20230202</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i1cb9060bc1554995858a89144c9522d0_D20230202-20230202" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjE3YmNmOTNiNjQ4ZTQ3Mzg5N2JkODY4ZTU3M2I4MDRiL3NlYzoxN2JjZjkzYjY0OGU0NzM4OTdiZDg2OGU1NzNiODA0Yl80L2ZyYWc6OTEyNTFjMzQyOGIxNDFkMGFiMzJmZjhlN2NiNTBjNWQvdGFibGU6NjM5Zjk0NmVlYmUxNDZmY2FkM2FiYTAyNDJkYTUxMzkvdGFibGVyYW5nZTo2MzlmOTQ2ZWViZTE0NmZjYWQzYWJhMDI0MmRhNTEzOV8yLTEtMS0xLTQzMDQz_f6a2203c-6f6b-481c-92d3-25686258c4c5">0001213037</ix:nonNumeric><ix:nonNumeric contextRef="i1cb9060bc1554995858a89144c9522d0_D20230202-20230202" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjE3YmNmOTNiNjQ4ZTQ3Mzg5N2JkODY4ZTU3M2I4MDRiL3NlYzoxN2JjZjkzYjY0OGU0NzM4OTdiZDg2OGU1NzNiODA0Yl80L2ZyYWc6OTEyNTFjMzQyOGIxNDFkMGFiMzJmZjhlN2NiNTBjNWQvdGFibGU6NjM5Zjk0NmVlYmUxNDZmY2FkM2FiYTAyNDJkYTUxMzkvdGFibGVyYW5nZTo2MzlmOTQ2ZWViZTE0NmZjYWQzYWJhMDI0MmRhNTEzOV8zLTEtMS0xLTQzMDQz_f099ed71-137b-4ba9-80db-f87a5f3cdf19">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="crdf-20230202.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i1cb9060bc1554995858a89144c9522d0_D20230202-20230202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-02</xbrli:startDate><xbrli:endDate>2023-02-02</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i17bcf93b648e473897bd868e573b804b_1"></div><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, DC 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="i1cb9060bc1554995858a89144c9522d0_D20230202-20230202" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjE3YmNmOTNiNjQ4ZTQ3Mzg5N2JkODY4ZTU3M2I4MDRiL3NlYzoxN2JjZjkzYjY0OGU0NzM4OTdiZDg2OGU1NzNiODA0Yl8xL2ZyYWc6YTZlODlmMzYxOTllNDViNjgzYTg2ODE2YzZjYTAwNTAvdGV4dHJlZ2lvbjphNmU4OWYzNjE5OWU0NWI2ODNhODY4MTZjNmNhMDA1MF8yNTIy_fcd555e7-1505-41a4-aa29-8aeec969eac0">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date of Report (Date of earliest event reported): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i1cb9060bc1554995858a89144c9522d0_D20230202-20230202" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjE3YmNmOTNiNjQ4ZTQ3Mzg5N2JkODY4ZTU3M2I4MDRiL3NlYzoxN2JjZjkzYjY0OGU0NzM4OTdiZDg2OGU1NzNiODA0Yl8xL2ZyYWc6YTZlODlmMzYxOTllNDViNjgzYTg2ODE2YzZjYTAwNTAvdGV4dHJlZ2lvbjphNmU4OWYzNjE5OWU0NWI2ODNhODY4MTZjNmNhMDA1MF8yMjg_ca52523a-d630-405e-9cb7-4e4a12d69383">February 2, 2023</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><img src="crdf-20230202_g1.jpg" alt="crdf-20230202_g1.jpg" style="height:44px;margin-bottom:5pt;vertical-align:text-bottom;width:157px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i1cb9060bc1554995858a89144c9522d0_D20230202-20230202" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjE3YmNmOTNiNjQ4ZTQ3Mzg5N2JkODY4ZTU3M2I4MDRiL3NlYzoxN2JjZjkzYjY0OGU0NzM4OTdiZDg2OGU1NzNiODA0Yl8xL2ZyYWc6YTZlODlmMzYxOTllNDViNjgzYTg2ODE2YzZjYTAwNTAvdGV4dHJlZ2lvbjphNmU4OWYzNjE5OWU0NWI2ODNhODY4MTZjNmNhMDA1MF8yNTMy_d0032a91-afa4-4f8a-9bdf-5d185f128d4f">Cardiff Oncology,&#160;Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.525%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i1cb9060bc1554995858a89144c9522d0_D20230202-20230202" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjE3YmNmOTNiNjQ4ZTQ3Mzg5N2JkODY4ZTU3M2I4MDRiL3NlYzoxN2JjZjkzYjY0OGU0NzM4OTdiZDg2OGU1NzNiODA0Yl8xL2ZyYWc6YTZlODlmMzYxOTllNDViNjgzYTg2ODE2YzZjYTAwNTAvdGFibGU6M2VlZWUxZTIxNjQ5NDFlNGI5ZWVjYjVhNjY2NDZkZGQvdGFibGVyYW5nZTozZWVlZTFlMjE2NDk0MWU0YjllZWNiNWE2NjY0NmRkZF8wLTAtMS0xLTQzMDQz_00ab37c4-b23c-433e-91bf-4bd1b757bf28">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i1cb9060bc1554995858a89144c9522d0_D20230202-20230202" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjE3YmNmOTNiNjQ4ZTQ3Mzg5N2JkODY4ZTU3M2I4MDRiL3NlYzoxN2JjZjkzYjY0OGU0NzM4OTdiZDg2OGU1NzNiODA0Yl8xL2ZyYWc6YTZlODlmMzYxOTllNDViNjgzYTg2ODE2YzZjYTAwNTAvdGFibGU6M2VlZWUxZTIxNjQ5NDFlNGI5ZWVjYjVhNjY2NDZkZGQvdGFibGVyYW5nZTozZWVlZTFlMjE2NDk0MWU0YjllZWNiNWE2NjY0NmRkZF8wLTEtMS0xLTQzMDQz_b4d24b9c-c600-4a35-b316-305c7c0cd54c">001-35558</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i1cb9060bc1554995858a89144c9522d0_D20230202-20230202" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjE3YmNmOTNiNjQ4ZTQ3Mzg5N2JkODY4ZTU3M2I4MDRiL3NlYzoxN2JjZjkzYjY0OGU0NzM4OTdiZDg2OGU1NzNiODA0Yl8xL2ZyYWc6YTZlODlmMzYxOTllNDViNjgzYTg2ODE2YzZjYTAwNTAvdGFibGU6M2VlZWUxZTIxNjQ5NDFlNGI5ZWVjYjVhNjY2NDZkZGQvdGFibGVyYW5nZTozZWVlZTFlMjE2NDk0MWU0YjllZWNiNWE2NjY0NmRkZF8wLTItMS0xLTQzMDQz_4fc2485d-48f3-499c-afac-a34522ae4013">27-2004382</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Commission File Number)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IRS Employer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">of incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identification No.)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i1cb9060bc1554995858a89144c9522d0_D20230202-20230202" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjE3YmNmOTNiNjQ4ZTQ3Mzg5N2JkODY4ZTU3M2I4MDRiL3NlYzoxN2JjZjkzYjY0OGU0NzM4OTdiZDg2OGU1NzNiODA0Yl8xL2ZyYWc6YTZlODlmMzYxOTllNDViNjgzYTg2ODE2YzZjYTAwNTAvdGV4dHJlZ2lvbjphNmU4OWYzNjE5OWU0NWI2ODNhODY4MTZjNmNhMDA1MF8yNTI5_c5ed254f-2e6a-4de2-88e7-ce5f6e0af877">11055 Flintkote Avenue</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i1cb9060bc1554995858a89144c9522d0_D20230202-20230202" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjE3YmNmOTNiNjQ4ZTQ3Mzg5N2JkODY4ZTU3M2I4MDRiL3NlYzoxN2JjZjkzYjY0OGU0NzM4OTdiZDg2OGU1NzNiODA0Yl8xL2ZyYWc6YTZlODlmMzYxOTllNDViNjgzYTg2ODE2YzZjYTAwNTAvdGV4dHJlZ2lvbjphNmU4OWYzNjE5OWU0NWI2ODNhODY4MTZjNmNhMDA1MF8yNTMz_0e52a425-00e4-4666-880b-684289613643">San Diego</ix:nonNumeric>, <ix:nonNumeric contextRef="i1cb9060bc1554995858a89144c9522d0_D20230202-20230202" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjE3YmNmOTNiNjQ4ZTQ3Mzg5N2JkODY4ZTU3M2I4MDRiL3NlYzoxN2JjZjkzYjY0OGU0NzM4OTdiZDg2OGU1NzNiODA0Yl8xL2ZyYWc6YTZlODlmMzYxOTllNDViNjgzYTg2ODE2YzZjYTAwNTAvdGV4dHJlZ2lvbjphNmU4OWYzNjE5OWU0NWI2ODNhODY4MTZjNmNhMDA1MF8yNTM0_ca4e5cf3-445f-4c66-ac70-c80a9e64ffaa">CA</ix:nonNumeric> <ix:nonNumeric contextRef="i1cb9060bc1554995858a89144c9522d0_D20230202-20230202" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjE3YmNmOTNiNjQ4ZTQ3Mzg5N2JkODY4ZTU3M2I4MDRiL3NlYzoxN2JjZjkzYjY0OGU0NzM4OTdiZDg2OGU1NzNiODA0Yl8xL2ZyYWc6YTZlODlmMzYxOTllNDViNjgzYTg2ODE2YzZjYTAwNTAvdGV4dHJlZ2lvbjphNmU4OWYzNjE5OWU0NWI2ODNhODY4MTZjNmNhMDA1MF8yNTMw_99c6815e-685e-40ff-a3f3-b5bc4dd77aa6">92121</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive offices)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant&#8217;s telephone number, including area code: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i1cb9060bc1554995858a89144c9522d0_D20230202-20230202" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjE3YmNmOTNiNjQ4ZTQ3Mzg5N2JkODY4ZTU3M2I4MDRiL3NlYzoxN2JjZjkzYjY0OGU0NzM4OTdiZDg2OGU1NzNiODA0Yl8xL2ZyYWc6YTZlODlmMzYxOTllNDViNjgzYTg2ODE2YzZjYTAwNTAvdGV4dHJlZ2lvbjphNmU4OWYzNjE5OWU0NWI2ODNhODY4MTZjNmNhMDA1MF8yNTI1_27532444-c844-47e7-84c1-f108c7d710f6">(858)</ix:nonNumeric> <ix:nonNumeric contextRef="i1cb9060bc1554995858a89144c9522d0_D20230202-20230202" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjE3YmNmOTNiNjQ4ZTQ3Mzg5N2JkODY4ZTU3M2I4MDRiL3NlYzoxN2JjZjkzYjY0OGU0NzM4OTdiZDg2OGU1NzNiODA0Yl8xL2ZyYWc6YTZlODlmMzYxOTllNDViNjgzYTg2ODE2YzZjYTAwNTAvdGV4dHJlZ2lvbjphNmU4OWYzNjE5OWU0NWI2ODNhODY4MTZjNmNhMDA1MF8yNTM1_e0e91766-ad20-4df8-95aa-ced02b04f81a">952-7570</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Former name or former address, if changed since last report)</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160; </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.140%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.257%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.143%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:3pt solid #ffffff;border-top:3pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title&#160;of&#160;each&#160;class:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="border-top:3pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading&#160;Symbol(s)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="border-right:3pt solid #ffffff;border-top:3pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name&#160;of&#160;each&#160;exchange&#160;on&#160;which&#160;registered:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></div></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1cb9060bc1554995858a89144c9522d0_D20230202-20230202" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjE3YmNmOTNiNjQ4ZTQ3Mzg5N2JkODY4ZTU3M2I4MDRiL3NlYzoxN2JjZjkzYjY0OGU0NzM4OTdiZDg2OGU1NzNiODA0Yl8xL2ZyYWc6YTZlODlmMzYxOTllNDViNjgzYTg2ODE2YzZjYTAwNTAvdGFibGU6NTYxMGNjMGZlMjUxNDc1NGFhYmViMDg3MzI3NjFjYWQvdGFibGVyYW5nZTo1NjEwY2MwZmUyNTE0NzU0YWFiZWIwODczMjc2MWNhZF8xLTAtMS0xLTQzMDQz_31731655-7ed4-4328-a044-25c207d7bd79">Common Stock</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1cb9060bc1554995858a89144c9522d0_D20230202-20230202" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjE3YmNmOTNiNjQ4ZTQ3Mzg5N2JkODY4ZTU3M2I4MDRiL3NlYzoxN2JjZjkzYjY0OGU0NzM4OTdiZDg2OGU1NzNiODA0Yl8xL2ZyYWc6YTZlODlmMzYxOTllNDViNjgzYTg2ODE2YzZjYTAwNTAvdGFibGU6NTYxMGNjMGZlMjUxNDc1NGFhYmViMDg3MzI3NjFjYWQvdGFibGVyYW5nZTo1NjEwY2MwZmUyNTE0NzU0YWFiZWIwODczMjc2MWNhZF8xLTItMS0xLTQzMDQz_9592acb5-9ba7-46b9-914b-1d0666117f8b">CRDF</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nasdaq Capital Market</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i1cb9060bc1554995858a89144c9522d0_D20230202-20230202" name="dei:WrittenCommunications" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjE3YmNmOTNiNjQ4ZTQ3Mzg5N2JkODY4ZTU3M2I4MDRiL3NlYzoxN2JjZjkzYjY0OGU0NzM4OTdiZDg2OGU1NzNiODA0Yl8xL2ZyYWc6YTZlODlmMzYxOTllNDViNjgzYTg2ODE2YzZjYTAwNTAvdGV4dHJlZ2lvbjphNmU4OWYzNjE5OWU0NWI2ODNhODY4MTZjNmNhMDA1MF8yNTM2_d7aa97c3-f2b9-4105-9ef4-23e53732000a">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Written communication pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i1cb9060bc1554995858a89144c9522d0_D20230202-20230202" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjE3YmNmOTNiNjQ4ZTQ3Mzg5N2JkODY4ZTU3M2I4MDRiL3NlYzoxN2JjZjkzYjY0OGU0NzM4OTdiZDg2OGU1NzNiODA0Yl8xL2ZyYWc6YTZlODlmMzYxOTllNDViNjgzYTg2ODE2YzZjYTAwNTAvdGV4dHJlZ2lvbjphNmU4OWYzNjE5OWU0NWI2ODNhODY4MTZjNmNhMDA1MF8yNTI2_4e791e3b-04b5-4fa6-86d1-e52f4db9ef95">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i1cb9060bc1554995858a89144c9522d0_D20230202-20230202" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjE3YmNmOTNiNjQ4ZTQ3Mzg5N2JkODY4ZTU3M2I4MDRiL3NlYzoxN2JjZjkzYjY0OGU0NzM4OTdiZDg2OGU1NzNiODA0Yl8xL2ZyYWc6YTZlODlmMzYxOTllNDViNjgzYTg2ODE2YzZjYTAwNTAvdGV4dHJlZ2lvbjphNmU4OWYzNjE5OWU0NWI2ODNhODY4MTZjNmNhMDA1MF8yNTIz_2ee45075-1142-4031-98a7-392fb68985cf">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i1cb9060bc1554995858a89144c9522d0_D20230202-20230202" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjE3YmNmOTNiNjQ4ZTQ3Mzg5N2JkODY4ZTU3M2I4MDRiL3NlYzoxN2JjZjkzYjY0OGU0NzM4OTdiZDg2OGU1NzNiODA0Yl8xL2ZyYWc6YTZlODlmMzYxOTllNDViNjgzYTg2ODE2YzZjYTAwNTAvdGV4dHJlZ2lvbjphNmU4OWYzNjE5OWU0NWI2ODNhODY4MTZjNmNhMDA1MF8yNTI3_f149c676-f9bf-432a-a330-d3403c4e5530">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">&#160;Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).&#160; Emerging growth company&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:138%"><ix:nonNumeric contextRef="i1cb9060bc1554995858a89144c9522d0_D20230202-20230202" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjE3YmNmOTNiNjQ4ZTQ3Mzg5N2JkODY4ZTU3M2I4MDRiL3NlYzoxN2JjZjkzYjY0OGU0NzM4OTdiZDg2OGU1NzNiODA0Yl8xL2ZyYWc6YTZlODlmMzYxOTllNDViNjgzYTg2ODE2YzZjYTAwNTAvdGV4dHJlZ2lvbjphNmU4OWYzNjE5OWU0NWI2ODNhODY4MTZjNmNhMDA1MF8yNTMx_0af40fea-e26e-4308-a798-8195ef04bc50">o</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:120%">o</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Item 5.02             Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 30, 2023, Cardiff Oncology, Inc. (the &#8220;Company&#8221;) appointed Dr. Fairooz Kabbinavar as Chief Medical Officer of the Company and entered into an employment agreement with Dr. Kabbinavar on January 31, 2023 (the &#8220;Kabbinavar Employment Agreement&#8221;).  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Kabbinavar Employment Agreement, Dr. Kabbinavar is entitled to receive an annual base salary of $480,000 and an annual performance bonus with a target amount equal to 45% of his annual base salary based upon the Board&#8217;s assessment of Dr. Kabbinavar&#8217;s and the Company&#8217;s attainment of goals as set by the Board in its sole discretion. In accordance with the Kabbinavar Employment Agreement, Dr. Kabbinavar was also granted a non-qualified option to purchase 425,000 shares of our common stock with an exercise price of $1.75 per share. The options were granted as inducement grants in accordance with Nasdaq Listing Rule 5635(c)(4).  25% of the shares subject to the option will vest on January 30, 2024 and the remaining shares vest in 36 equal monthly installments thereafter, subject to Dr. Kabbinavar&#8217;s continued service. In addition, the Kabbinavar Employment Agreement contains non-competition and non-solicitation provisions. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the Kabbinavar Employment Agreement, if Dr. Kabbinavar&#8217;s employment is terminated by the Company for cause or as a result of Dr. Kabbinavar&#8217;s death or permanent disability, or if Dr. Kabbinavar terminates his employment agreement voluntarily, Dr. Kabbinavar will be entitled to receive a lump sum equal to (i) any portion of unpaid base compensation then due for periods prior to termination, (ii) any bonus earned but not yet paid through the date of his termination, and (iii) all business expenses reasonably and necessarily incurred by Dr. Kabbinavar prior to the date of termination. If Dr. Kabbinavar&#8217;s employment is terminated by the Company without cause or by Dr. Kabbinavar for good reason, Dr. Kabbinavar will be entitled to receive the amounts due upon termination of his employment by the Company for cause or as a result of his death or permanent disability, or upon termination by Dr. Kabbinavar of his employment voluntarily, in addition to (provided that Dr. Kabbinavar executes a written release with respect to certain matters) a severance payment equal to his base compensation for 12 months from the date of termination and the bonus and any benefits that Dr. Kabbinavar would be eligible for during such 12 month period. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if Dr. Kabbinavar&#8217;s employment is terminated: (a) by the Company without cause within 12 months prior to a change of control (as defined in the Kabbinavar Employment Agreement) that was pending during such 12 month period, (b) by Dr. Kabbinavar for good reason within 12 months after a change of control, or (c) by the Company without cause at any time upon or within 12 months after a change of control, Dr. Kabbinavar will be entitled to receive the amounts due upon termination of his employment by the Company for cause or as a result of his death or permanent disability, or upon termination by Dr. Kabbinavar of his employment voluntarily, in addition to the severance payments due if Dr. Kabbinavar&#8217;s employment is terminated by the Company without cause or by Dr. Kabbinavar for good reason, and all of Dr. Kabbinavar&#8217;s unvested stock options and other equity awards would immediately vest and become fully exercisable (x) in the event a change of control transaction is pending, for a period of six months following the date of termination, and (y) in the event a change of control transaction is not then pending, for the period of time set forth in the applicable agreement evidencing the award.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no arrangements or understandings between Dr. Kabbinavar and any other person pursuant to which he was selected as an officer of the Company, and there is no family relationship between Dr. Kabbinavar and any of the Company&#8217;s other directors or executive officers.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing description of the Kabbinavar Employment Agreement is not complete and is qualified in its entirety by reference to the Kabbinavar Employment Agreement, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference. </span></div><div style="padding-left:72pt;text-indent:-72pt"><span><br/></span></div><div style="padding-left:72pt;text-indent:-72pt"><span><br/></span></div><div style="padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Item 8.01             Other Events.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 2, 2023, the Company issued a press release announcing the appointment of Dr. Kabbinavar as Chief Medical Officer.    A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.  </span></div><div style="text-indent:27pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01. Financial Statements and Exhibits</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Exhibits.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.363%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.437%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a101ex020223.htm">Employment Agreement dated January 31, 2023 by and between Dr. Fairooz Kabbinavar and Cardiff Oncology, Inc.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a991ex020223.htm">Press Release of Cardiff Oncology, Inc. dated February 2, 2023</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SIGNATURE</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> February 2, 2023</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.704%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.451%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CARDIFF ONCOLOGY,&#160;INC.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Mark Erlander</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark Erlander</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>a101ex020223.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ie050a4a656ed46e6a2b2eb0df44e02ff_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EMPLOYMENT AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Employment Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) is made and entered into effective as of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">February __, 2023 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), by and between Fairooz Kabbinavar, MD, FACP (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and Cardiff Oncology, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">R E C I T A L S</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, the Company desires to employ Executive, and Executive desires to be employed by the Company, in each case effective as of the Effective Date&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, in connection with the foregoing, Executive shall be required to perform Executive&#8217;s duties and obligations hereunder on behalf of the Company, as appropriate, and such duties and obligations shall be enforceable by the Company&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, this Agreement supersedes any and all prior term sheets, employment agreements or similar agreements by and between Executive and the Company.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In consideration of the mutual covenants herein contained and the employment of Executive by the Company, the parties agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Definition of Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The following terms referred to in this Agreement shall have the following meanings&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any of the following&#58;  (i) the commission of a material act of fraud, embezzlement or misappropriation, which is intended to result in substantial personal enrichment of Executive in connection with Executive&#8217;s employment with the Company&#59; (ii)&#160;Executive&#8217;s willful misconduct, gross negligence, act of dishonesty or breach of trust in connection with Executive&#8217;s employment&#59; (iii)&#160;Executive&#8217;s indictment for or charge with (and in connection with which there is the commencement of a criminal trial), or plea of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">nolo contendere</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, to a crime constituting a felony (other than traffic-related offenses) or any other criminal offense involving fraud, dishonesty, misappropriation or serious moral turpitude&#59; (iv)&#160;Executive&#8217;s breach of any non-solicitation or non-competition obligations to the Company or its affiliates, including without limitation, those set forth in Section 15(a) and Section 15(b) of this Agreement or Executive&#8217;s willful, grossly negligent, or reckless breach of any confidentiality obligations to the Company or its affiliates, including, without limitation, those set forth in Section 14 of this Agreement and the Confidentiality and Inventions Agreement attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#59; or (v)&#160;Executive&#8217;s (1)&#160;material failure to perform Executive&#8217;s duties as set forth in this Agreement, and (2)&#160;failure to &#8220;cure&#8221; any such failure within thirty (30)&#160;days after receipt of written notice from the Company delineating the specific acts that constituted such material failure and the specific actions necessary, if any, to &#8220;cure&#8221; such failure.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the occurrence of any of the following events&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">the date on which any &#8220;person&#8221; (as such term is used in Sections&#160;13(d) and 14(d) of the Securities Exchange Act of 1934, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)), obtains &#8220;beneficial ownership&#8221; (as defined in Rule&#160;13d-3 of the Exchange Act) or a pecuniary interest in fifty percent (50%)&#160;or more of the combined voting power of the Company&#8217;s then outstanding securities (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Voting Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">the consummation of a merger, consolidation, reorganization, or similar transaction involving the Company, other than a transaction&#58;  (1) in which substantially all of the holders of the Voting Stock immediately prior to such transaction hold or receive directly or indirectly more than fifty percent (50%)&#160;or more of the voting stock of the resulting entity or a parent company thereof, in substantially the same proportions as their ownership of the Company immediately prior to the transaction&#59; or (2)&#160;in which the holders of the Company&#8217;s capital stock immediately before such transaction will, immediately after such transaction, hold as a group on a fully diluted basis the ability to elect at least a majority of the authorized directors of the surviving entity (or a parent company)&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">there is consummated a sale, lease, license or disposition of all or substantially all of the consolidated assets of the Company and its subsidiaries, other than a sale, lease, license or disposition of all or substantially all of the consolidated assets of the Company and its subsidiaries to an entity, more than fifty percent (50%)&#160;of the combined voting power of the voting securities of which are owned by stockholders of the Company in substantially the same proportions as their ownership of the Company immediately prior to such sale, lease, license or disposition.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means totally and permanently disabled as defined in the Company&#8217;s disability benefit plan applicable to senior executive officers as in effect on the date thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean without Executive&#8217;s express written consent any of the following&#58;  (i) a material reduction of Executive&#8217;s duties, position or responsibilities relative to Executive&#8217;s duties, position or responsibilities in effect immediately prior to such reduction, or the removal of Executive from such position, duties or responsibilities&#59; (ii)&#160;a reduction of Executive&#8217;s compensation as in effect immediately prior to such reduction&#59; (iii)&#160;the relocation of Executive to a facility or a location more than fifty (50)&#160;miles from the Company&#8217;s then current principal location&#59; or (iv)&#160;a material breach by the Company of this Agreement.  Any Good Reason termination will require thirty&#160;(30) days advance written notice by Executive of the event giving rise to Good Reason within sixty&#160;(60) days after Executive first learns of the applicable event, and will not be effective unless the Company has not cured the Good Reason event within such thirty&#160;(30) day notice period.  In order for Executive to resign for Good Reason, Executive must resign from Executive&#8217;s employment within sixty&#160;(60) days after the failure of the Company to cure a Good Reason event.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Duties and Scope of Position</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  During the Term (as defined below), Executive will serve as Chief Medical Officer of the Company, reporting to the Chief Executive Officer of the Company, and assuming and discharging such responsibilities as are commensurate with Executive&#8217;s position.  During the Term, Executive will provide services in a manner that will faithfully and diligently further the business of the Company and will devote a substantial portion of Executive&#8217;s business time, attention and energy thereto.  Notwithstanding the foregoing, nothing in this Agreement shall restrict Executive from managing Executive&#8217;s personal investments, or serving on civic or charitable boards or committees, provided that no such activities unduly interfere, individually or in the aggregate, with the performance of Executive&#8217;s obligations under this Agreement, provided that Executive shall honor the non-competition and non-solicitation terms as per Section&#160;15 below.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The term of Executive&#8217;s employment under this Agreement shall commence as of the Effective Date and shall continue until February __, 2026, unless earlier terminated in accordance with Section&#160;9 hereof.  The term of Executive&#8217;s employment shall be automatically renewed for successive one (1)&#160;year periods until the Executive or the Company delivers to the other party a written notice of their intent not to renew such employment, such written notice to be delivered at least sixty (60)&#160;days prior to the expiration of the then-effective </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Term as that term is defined below.  The period commencing as of the Effective Date and ending on Executive&#8217;s last date of employment with the Company under this Agreement is the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and the end of the Term is referred to herein as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Expiration Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Base Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company shall pay to Executive a base compensation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Base Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) of $480,000 per year (prorated for any partial year), payable at such times as the Company customarily pays its other senior executives (but in any event no less often than monthly).  In addition, each year during the Term, Executive shall be reviewed for purposes of determining the appropriateness of Executive&#8217;s Base Compensation hereunder.  The Base Compensation shall be subject to all federal, state and local payroll tax withholding and any other withholdings required by law.  For purposes of the Agreement, the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Base Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; as of any point in time shall refer to the Base Compensation as adjusted pursuant to this Section&#160;4.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Benefits&#59; Expense Reimbursement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  During the Term, Executive shall be entitled to participate in all company employee benefit plans.  In the event Executive elects to pay to a self-funded health insurance program, Executive shall be reimbursed by the Company for such costs up to the maximum amount the Company would be obligated to pay for similar benefits pursuant to its health insurance plans.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  During the Term, the Company shall promptly reimburse Executive for all expenses reasonably and necessarily incurred by Executive in connection with the business of the Company, consistent with Company policies in effect from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Target Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In addition to Executive&#8217;s Base Compensation, during the Term Executive shall be given the opportunity to earn an annual bonus (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) of up to 45% of Base Compensation.  The Bonus shall be earned by Executive upon the Company&#8217;s achievement of performance milestones for a fiscal year (in each case, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Target Year</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) to be mutually agreed upon by the Executive and the Board or its compensation committee.  In the event Executive is employed by the Company for less than the full Target Year for which a Bonus is earned pursuant to this Section &#160;6, Executive shall be entitled to receive a pro-rated Bonus for such Target Year based on the number of days Executive was employed by the Company during such Target Year divided by 365.  The determinations of the Board or its compensation committee with respect to Bonuses will be final and binding.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Equity Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive will be granted an equity-based compensation award (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) in such amounts and subject to such terms and conditions that are consistent with, and no less favorable to Executive than the terms and conditions set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> attached hereto.  Upon termination of Executive&#8217;s employment, the treatment of any portion of outstanding Award shall be determined in accordance with the terms of any agreements governing such award (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Award Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Executive shall remain eligible to receive additional equity-based compensation awards as the Company may grant from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Intentionally omitted</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Termination by the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject to the obligations of the Company set forth in Section&#160;10 below, the Company may terminate Executive&#8217;s employment at any time and for any reason (or no reason), and with or without Cause, and without prejudice to any other right or remedy to which the Company or Executive may be entitled at law or in equity or under this Agreement.  Notwithstanding the foregoing, in the event the Company desires to terminate </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Executive&#8217;s employment without Cause, the Company shall give the Executive not less than sixty (60)&#160;days advance written notice.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Termination by Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive may voluntarily terminate the Term upon sixty (60)&#160;days&#8217; prior written notice for any reason or no reason.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Termination for Death or Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject to the obligations of the Company set forth in Section&#160;10 below, Executive&#8217;s employment shall terminate automatically upon Executive&#8217;s death.  Subject to the obligations of the Company set forth in Section&#160;10 below, in the event Executive is unable to perform Executive&#8217;s duties as a result of Disability during the Term, the Company shall have the right to terminate the employment of Executive by providing written notice of the effective date of such termination.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Payments Upon Termination of Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Termination for Cause, Death or Disability or Termination by Executive without Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event that Executive&#8217;s employment hereunder is terminated during the Term by the Company for Cause, as a result of Executive&#8217;s death or Disability, or voluntarily by Executive without Good Reason, the Company shall compensate Executive (or in the case of death, Executive&#8217;s estate) as follows&#58;  on the date of termination, the Company shall pay Executive a lump sum amount equal to (i)&#160;any portion of unpaid Base Compensation then due for periods prior to the effective date of termination&#59; (ii)&#160;any Bonus and Options earned and not yet paid or granted, as applicable, through the date of termination&#59; and (iii)&#160;within 2-1&#47;2&#160;months following submission of proper expense reports by Executive or Executive&#8217;s estate, all expenses reasonably and necessarily incurred by Executive in connection with the business of the Company prior to the date of termination.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Termination by Company Without Cause or by Executive for Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event that Executive&#8217;s employment is terminated during the Term by the Company without Cause or by Executive for Good Reason, the Company shall compensate Executive as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">on the date of termination, the Company shall pay Executive a lump sum amount equal to (A)&#160;any portion of unpaid Base Compensation then due for periods prior to the effective date of termination&#59; (B)&#160;any Bonus and Options earned and not yet paid or granted, as applicable, through the date of termination&#59; and (C)&#160;within 2-1&#47;2&#160;months following submission of proper expense reports by Executive, all expenses reasonably and necessarily incurred by Executive in connection with the business of the Company prior to the date of termination&#59; and, provided that Executive executes a written release pursuant to Section 10(e) below, the Company shall pay Executive the Base Compensation for twelve (12)&#160;months from the date of termination, the potential Bonus the Executive is or would be eligible for pursuant to Section&#160;6 herein during such twelve (12)&#160;month period following the termination and any benefits (or benefits reimbursement payments) pursuant to Section&#160;5 herein that the Executive is or would be eligible for during such twelve (12)&#160;month period.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Termination in the Context of a Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding anything in Section&#160;10(a) or 10(b) herein to the contrary, in the event of Executive&#8217;s termination of employment with the Company either (i)&#160;by the Company without Cause at any time within twelve (12)&#160;months prior to the consummation of a Change of Control if, prior to, or as of such termination, a Change of Control transaction was Pending (as defined in Section&#160;10(d) below) at any time during such twelve (12)-month period, (ii)&#160;by Executive for Good Reason at any time within twelve (12)&#160;months after the consummation of a Change of Control, or (iii)&#160;by the Company without Cause at any time upon or within twelve (12)&#160;months after the consummation </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of a Change of Control, then, Executive shall be entitled to the following payments and other benefits&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">on the date of termination (except as specified in clause&#160;(C)), the Company shall pay Executive a lump sum amount equal to (A)&#160;any portion of unpaid Base Compensation then due for periods prior to the effective date of termination&#59; (B)&#160;any Bonus earned and not yet paid through the date of termination&#59; and (C)&#160;within 2-1&#47;2&#160;months following submission of proper expense reports by Executive, all expenses reasonably and necessarily incurred by Executive in connection with the business of the Company prior to the date of termination&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">on the date of termination, provided that Executive executes a written release pursuant to Section 10(e) below, the Company shall pay to Executive a lump sum amount equal to twelve (12)&#160;months of Executive&#8217;s Base Compensation then in effect as of the day of termination, the maximum Bonus the Executive is or would be eligible for pursuant to Section&#160;6 herein during such twelve (12)&#160;month period and any benefits pursuant to Section&#160;5 herein that the Executive is or would be eligible for during such twelve (12)&#160;month period&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">notwithstanding any provision of any stock incentive plan, stock option agreement, restricted stock agreement or other agreement relating to capital stock of the Company, and provided that Executive executes a written release pursuant to Section 10(e) below, all of the shares and equity awards held by Executive that are then unvested shall immediately vest and, with respect to all options, warrants and other convertible securities of the Company beneficially held by Executive, become fully exercisable for (A)&#160;a period of six months following the date of termination only if at the time of such termination there is a Change of Control transaction Pending (as defined in Section&#160;10(d) below) or (B)&#160;if clause&#160;(A) does not apply, then such period of time set forth in the agreement evidencing the security&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">Severance benefits under this Section&#160;10(c) and Section&#160;10(b) above shall be mutually exclusive and severance under one such section shall prohibit severance under the other.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In order to effectuate the provisions of Section&#160;10(c)(iii) hereof, in the event that Executive&#8217;s employment is terminated during the Term by the Company without Cause or by Executive for Good Reason, no equity award held by Executive shall expire or terminate prior to the earlier to occur of (a)&#160;ten (10)&#160;years after the date of the award and (b)&#160;fifteen (15)&#160;months after Executive&#8217;s termination of employment with the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Definition of &#8220;Pending</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.&#8221;  For purposes of Section&#160;10(c) herein, a Change of Control transaction shall be deemed to be &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Pending</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; each time any of the following circumstances exist&#58;  (A) the Company and a third party have entered into a confidentiality agreement that has been signed by a duly-authorized officer of the Company and that is related to a potential Change of Control transaction&#59; (B)&#160;the Company has received a written expression of interest from a third party, including a binding or non-binding term sheet or letter of intent, related to a potential Change of Control transaction&#59; or (C)&#160;a third party has publicly announced, through a filing with the Securities and Exchange Commission, its intent to commence a tender offer or similar transaction to acquire 50% or more of the outstanding voting interests of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Conditions to Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All payments and benefits due to Executive under this Section 10 that are made subject to this Section 10(e) on 10, (such payments, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Severance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), shall only be payable if Executive (or Executive&#8217;s beneficiary or estate) delivers to the Company and does not revoke (under the terms of applicable law) a general release of all claims substantially in the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit&#160;A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Such general release shall be executed </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and delivered (and no longer subject to revocation) within fifty-five&#160;(55) days following termination.  Failure to timely execute and return such release or revocation shall be a waiver by Executive of Executive&#8217;s right to any Severance.  If Executive&#8217;s review and revocation period for the release of claims required pursuant to this Section spans two of Executive&#8217;s taxable years, the first payment shall be made on the first regularly scheduled payroll date of the later taxable year following the effective date of such release of claims and shall include all amounts accrued prior thereto.  In addition, Severance shall be conditioned on Executive&#8217;s compliance with Section 15 hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Code Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">The parties agree that this Agreement shall be interpreted to comply with or be exempt from Section 409A of the Code and the regulations and guidance promulgated thereunder to the extent applicable (collectively &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Code Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and all provisions of this Agreement shall be construed in a manner consistent with the requirements for avoiding taxes or penalties under Code Section 409A. In no event whatsoever will the Company be liable for any additional tax, interest or penalties that may be imposed on Executive under Code Section&#160;409A or any damages for failing to comply with Code Section 409A.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">A termination of employment shall not be deemed to have occurred for purposes of any provision of this Agreement providing for the payment of any amounts or benefits considered &#8220;nonqualified deferred compensation&#8221; under Code Section 409A upon or following a termination of employment unless such termination is also a &#8220;separation from service&#8221; within the meaning of Code Section 409A and, for purposes of any such provision of this Agreement, references to a &#8220;termination,&#8221; &#8220;termination of employment&#8221; or like terms shall mean &#8220;separation from service.&#8221; If Executive is deemed on the date of termination to be a &#8220;specified employee&#8221; within the meaning of that term under Code Section 409A(a)(2)(B), then with regard to any payment or the provision of any benefit that is considered nonqualified deferred compensation under Code Section 409A payable on account of a &#8220;separation from service,&#8221; such payment or benefit shall be made or provided at the date which is the earlier of (i) the expiration of the six&#160;(6)-month period measured from the date of such &#8220;separation from service&#8221; of Executive, and (ii) the date of Executive&#8217;s death (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Delay Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). Upon the expiration of the Delay Period, all payments and benefits delayed pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13.7(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (whether they would have otherwise been payable in a single sum or in installments in the absence of such delay) shall be paid or reimbursed on the first business day following the expiration of the Delay Period to Executive in a lump sum, and any remaining payments and benefits due under this Agreement shall be paid or provided in accordance with the normal payment dates specified for them herein.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">With regard to any provision herein that provides for reimbursement of costs and expenses or in-kind benefits, except as permitted by Code Section 409A, (i) the right to reimbursement or in-kind benefits shall not be subject to liquidation or exchange for another benefit, (ii) the amount of expenses eligible for reimbursement, or in-kind benefits, provided during any taxable year shall not affect the expenses eligible for reimbursement, or in-kind benefits, to be provided in any other taxable year, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that, this clause (ii) shall not be violated with regard to expenses reimbursed under any arrangement covered by Internal Revenue Code Section 105(b) solely because such expenses are subject to a limit related to the period the arrangement is in effect and (iii) such payments shall be made on or before the last day of Executive&#8217;s taxable year following the taxable year in which the expense occurred.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">For purposes of Code Section 409A, Executive&#8217;s right to receive any installment payments pursuant to this Agreement shall be treated as a right to receive a series of separate and distinct payments. Whenever a payment under this Agreement specifies a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">payment period with reference to a number of days (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, &#8220;payment shall be made within thirty (30) days following the date of termination&#8221;), the actual date of payment within the specified period shall be within the sole discretion of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Successors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any successor to the Company (whether direct or indirect and whether by purchase, lease, merger, consolidation, liquidation or otherwise) to all or substantially all of the Company's business and&#47;or assets or otherwise pursuant to a Change of Control shall assume the Company's obligations under this Agreement and agree expressly in writing delivered to Executive, at or prior to such Change of Control, to perform the Company&#8217;s obligations under this Agreement in the same manner and to the same extent as the Company would be required to perform such obligations in the absence of a Change of Control.  For all purposes under this Agreement, the term &#8220;Company&#8221; shall include any successor to the Company's business and&#47;or assets (including any parent company to the Company), whether or not in connection with a Change of Control, which becomes bound by the terms of this Agreement by contract, operation of law or otherwise.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notices and all other communications contemplated by this Agreement shall be in writing and shall be deemed to have been duly given (a)&#160;when personally delivered (if to the Company, addressed to its Secretary at the Company&#8217;s principal place of business on a non-holiday weekday between the hours of 9 a.m. and 5 p.m.&#59; if to Executive, via personal service to Executive&#8217;s last known residence) or (b)&#160;three business days following the date it is mailed by U.S.&#160;registered or certified mail, return receipt requested and postage prepaid.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive recognizes and acknowledges that by reason of Executive&#8217;s employment by and service to the Company before, during and, if applicable, after the Term, Executive will have access to certain confidential and proprietary information relating to the Company&#8217;s business, which may include, but is not limited to, trade secrets, trade &#8220;know-how,&#8221; product development techniques and plans, formulas, customer lists and addresses, financing services, funding programs, cost and pricing information, marketing and sales techniques, strategy and programs, computer programs and software and financial information (collectively referred to herein as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Executive acknowledges that such Confidential Information is a valuable and unique asset of the Company and Executive covenants that Executive will not, unless expressly authorized in writing by the Company, at any time during the course of Executive&#8217;s employment use any Confidential Information or divulge or disclose any Confidential Information to any person, firm or corporation except in connection with the performance of Executive&#8217;s duties for and on behalf of the Company and in a manner consistent with the Company&#8217;s policies regarding Confidential Information.  Executive also covenants that at any time after the termination of such employment, directly or indirectly, Executive will not use any Confidential Information or divulge or disclose any Confidential Information to any person, firm or corporation, unless such information is in the public domain through no fault of Executive or except when required to do so by a court of law, by any governmental agency having supervisory authority over the business of the Company or by any administrative or legislative body (including a committee thereof) with apparent jurisdiction to order Executive to divulge, disclose or make accessible such information.  All written Confidential Information (including, without limitation, in any computer or other electronic format) which comes into Executive&#8217;s possession during the course of Executive&#8217;s employment shall remain the property of the Company.  Unless expressly authorized in writing by the Company, Executive shall not remove any written Confidential Information from the Company&#8217;s premises, except in connection with the performance of Executive&#8217;s duties for and on behalf of the Company and in a manner consistent with the Company&#8217;s policies regarding Confidential Information.  Upon termination of Executive&#8217;s employment, the Executive agrees to immediately return to the Company all written Confidential Information (including, without limitation, in any computer or other electronic format) in Executive&#8217;s possession.  As a condition of Executive&#8217;s employment with the Company and in order to protect the Company&#8217;s interest in such </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">proprietary information, the Company shall require Executive&#8217;s execution of a Confidentiality Agreement and Inventions Agreement in the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit&#160;B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, and incorporated herein by this reference.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Non-Competition&#59; Non-Solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Non-Compete</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Executive hereby covenants and agrees that during the Term and for a period of one year following the Expiration Date, the Executive will not, without the prior written consent of the Company, directly or indirectly, on Executive&#8217;s own behalf or in the service or on behalf of others, whether or not for compensation, engage in any business activity, or have any interest in any person, firm, corporation or business, through a subsidiary or parent entity or other entity (whether as a shareholder, agent, joint venturer, security holder, trustee, partner, Executive, creditor lending credit or money for the purpose of establishing or operating any such business, partner or otherwise) with any Competing Business in the Covered Area.  For the purpose of this Section&#160;15 (a), (i) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Competing Business</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the current business of the Company and (ii) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Covered Area</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means all geographical areas of the United States and other foreign jurisdictions where Company then has offices and&#47;or sells its products directly or indirectly through distributors and&#47;or other sales agents.  Notwithstanding the foregoing, the Executive may own shares of companies whose securities are publicly traded, so long as ownership of such securities do not constitute more than one percent (1%)&#160;of the outstanding securities of any such company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Non-Solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive further agrees that during the Term and for a period of one (1)&#160;year from the Expiration Date, the Executive will not divert any business of the Company and&#47;or its affiliates or any customers or suppliers of the Company and&#47;or the Company&#8217;s and&#47;or its affiliates&#8217; business to any other person, entity or competitor, or induce or attempt to induce, directly or indirectly, any person to leave his or her employment with the Company and&#47;or its affiliates&#59; provided, however, that the foregoing provisions shall not apply to a general advertisement or solicitation program that is not specifically targeted at such employees.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive acknowledges and agrees that Executive&#8217;s obligations provided herein are necessary and reasonable in order to protect the Company and its affiliates and their respective business and Executive expressly agrees that monetary damages would be inadequate to compensate the Company and&#47;or its affiliates for any breach by Executive of Executive&#8217;s covenants and agreements set forth herein.  Accordingly, Executive agrees and acknowledges that any such violation of this Section&#160;15 will cause irreparable injury to the Company and that, in addition to any other remedies that may be available, in law, in equity or otherwise, the Company and its affiliates shall be entitled to seek injunctive relief against the breach of this Section&#160;15 or the continuation of any such breach by the Executive without the necessity of proving actual damages.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Employment Relationship</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive&#8217;s employment with the Company will be &#8220;at will,&#8221; meaning that either Executive or the Company may terminate Executive&#8217;s employment at any time and for any reason, with or without Cause or Good Reason.  Any contrary representations that may have been made to Executive are superseded by this Agreement.  This is the full and complete agreement between Executive and the Company on this term.  Although Executive&#8217;s duties, title, compensation and benefits, as well as the Company&#8217;s personnel policies and procedures, may change from time-to-time, the &#8220;at will&#8221; nature of Executive&#8217;s employment may only be changed in an express written agreement signed by Executive and a duly authorized officer of the Company (other than Executive).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Miscellaneous Provisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Sections&#160;1, 5, 6, 10, 11, 13, 14, 15 and 17 herein, including this Section&#160;17(a), shall survive the termination of Executive&#8217;s employment with the Company, the expiration of this Agreement and the termination of this Agreement for any reason.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Modifications&#59; No Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  No provision of this Agreement may be modified, waived or discharged unless the modification, waiver or discharge is agreed to in writing and signed by Executive and by an authorized officer of the Company (other than Executive).  No waiver by either party of any breach of, or of compliance with, any condition or provision of this Agreement by the other party shall be considered a waiver of any other condition or provision or of the same condition or provision at another time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement supersedes, amends and restates all prior agreements and understandings between the parties, oral or written, including, without limitation, the Executive Agreement.  No modification, termination or attempted waiver shall be valid unless in writing, signed by the party against whom such modification, termination or waiver is sought to be enforced.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Choice of Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The validity, interpretation, construction and performance of this Agreement shall be governed by the internal substantive laws, but not the conflicts of law rules, of the State of California.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The invalidity or unenforceability of any provision or provisions of this Agreement shall not affect the validity or enforceability of any other provision hereof, which shall remain in full force and effect.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement may be executed in separate counterparts, any one of which need not contain signatures of more than one party, and may be delivered by facsimile or other electronic means, but all of which shall be deemed originals and taken together will constitute one and the same Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The headings of the Articles and Sections hereof are inserted for convenience only and shall not be deemed to constitute a part hereof nor to affect the meaning thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Construction of Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event of a conflict between the text of the Agreement and any summary, description or other information regarding the Agreement, the text of the Agreement shall control.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;Remainder of Page Intentionally Left Blank&#93;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9-</font></div></div></div><div id="ie050a4a656ed46e6a2b2eb0df44e02ff_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, each of the parties has executed this Agreement, in the case of the Company by its duly authorized officer, as of the day and year first above written.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br><br><br>COMPANY&#58;&#160;&#160;&#160;&#160;Cardiff Oncology, Inc.</font></div><div style="margin-bottom:12pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Mark Erlander</font></div><div style="margin-bottom:12pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Mark Erlander</font></div><div style="margin-bottom:12pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Chief Executive Officer</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br><br><br>EXECUTIVE&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Fairooz Kabbinavar<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br>&#160;&#160;&#160;&#160;Fairooz Kabbinavar, MD, FACP</font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit&#160;A<br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Form of Release Agreement</font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit&#160;B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><br><br>Confidentiality and Inventions Agreement</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit C</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EQUITY TERMS</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:63.58pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.076%"><tr><td style="width:1.0%"></td><td style="width:36.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:61.400%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Type of Award<br>(&#8220;Award&#8221;)</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:38.75pt;padding-right:2.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">An inducement grant under Nasdaq Rule </font><font style="background-color:#ffffff;color:#202124;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5635(c)(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:38.75pt;padding-right:2.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">Executive&#8217;s Award to equal 425,000 shares.</font></div><div style="margin-bottom:12pt;padding-left:38.75pt;padding-right:2.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">Award is evidenced by agreement executed by Executive and the Company.</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Vesting of Award</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:38.75pt;padding-right:2.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">25% vest one year after date of grant and the remainder vest in monthly equal amounts over 36 months beginning one year and one month after date of grant</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Termination of Service for Cause, resignation with&#47;without Cause, death &#38; disability, etc.</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:38.75pt;padding-right:2.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">ninety (90) days following the date of the Executive&#8217;s termination of employment with the Company and its Affiliates for any reason other than for Cause or due to the Executive&#8217;s death or Disability&#59; </font></div><div style="padding-left:38.75pt;padding-right:2.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">six (6) months following the date of the Executive&#8217;s termination of employment with the Company and its Affiliates due to the Executive&#8217;s death or Disability.</font></div><div style="margin-bottom:12pt;padding-left:38.75pt;padding-right:2.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">The entire Award (whether vested or unvested) held by the Executive immediately prior to the cessation of the Executive&#8217;s employment shall immediately terminate upon such cessation if such cessation of employment was for Cause</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>a991ex020223.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="if37e3b629b1e49f3a225f88d3d384389_1"></div><div style="min-height:42.48pt;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div><div><img alt="image_0.jpg" src="image_0.jpg" style="height:43px;margin-bottom:5pt;vertical-align:text-bottom;width:159px"></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Cardiff Oncology Announces the Appointment of Fairooz Kabbinavar, MD, FACP, as Chief Medical Officer</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">  Brings world class capabilities and deep expertise in colorectal cancer and other solid tumor indications to advance the clinical development of onvansertib  </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Served as the lead investigator for two practice-changing trials of bevacizumab (Avastin&#174;) combinations leading to the approval of bevacizumab in metastatic colorectal cancer (mCRC)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">1,2</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SAN DIEGO, February 2, 2023 &#8211; Cardiff Oncology, Inc. (Nasdaq&#58; CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers, today announced that it has strengthened its leadership team with the appointment of Fairooz Kabbinavar, MD, FACP, as chief medical officer (CMO).  Dr. Kabbinavar will oversee the clinical development program for the Company&#8217;s investigational drug onvansertib and will report directly to Chief Executive Officer, Mark Erlander, PhD.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Dr. Kabbinavar joins Cardiff Oncology with more than 30 years of experience that bridges both the academic and biotech&#47;pharmaceutical sectors. He spent 25 years as an academic oncologist at the University of California, Los Angeles (UCLA), holding appointments including professor of medicine and urologic oncology. He joined the biotech industry as the principal medical director in Genentech&#8217;s immuno-oncology program, where he led the clinical development of atezolizumab (TECENTRIQ&#174;) in extensive stage small cell lung cancer and oversaw the filing of the supplemental biologics license application that led to the drug&#8217;s FDA approval. Most recently, Dr. Kabbinavar was the global head of research and development at Huyabio International. Prior to joining Huyabio, he served as senior vice president (SVP) of clinical research and development at Puma Biotechnology, and CMO and SVP of clinical development at Tocagen, Inc.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;As both a clinical oncologist and biopharma executive, Fairooz brings deep knowledge of colorectal cancer, our lead indication for onvansertib, as well as other solid tumor cancers,&#8221; said Mark Erlander, PhD, chief executive officer of Cardiff Oncology. &#8220;His experience guiding the development and registration of high-impact oncology drugs adds critical and relevant expertise to the Cardiff team. The deep relationships Fairooz has with investigators and clinical trial sites worldwide, including serving as lead investigator for two practice-changing trials leading to the approval of bevacizumab in</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">mCRC, will be invaluable to expediting our clinical program. In addition, his experience successfully navigating the regulatory process in previous industry roles comes at an opportune time in the clinical development of onvansertib.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Dr. Kabbinavar commented, &#8220;I&#8217;m excited to join the Cardiff Oncology team to advance the clinical development of onvansertib for colorectal cancer patients specifically, and also for patients with other cancers. I&#8217;m encouraged by the response rates observed in the Phase 1b&#47;2 trial of onvansertib in KRAS-mutated mCRC, which are well above historical standard-of-care responses. A significant finding in this trial is the potential synergy between onvansertib and bevacizumab, which could lead to a novel paradigm in the management of patients with mCRC. I&#8217;m eager to bring my passion for oncology drug development to Cardiff Oncology.&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">While at UCLA, Dr. Kabbinavar served as the lead investigator on two practice-changing clinical trials of bevacizumab (Avastin&#174;) combinations leading to approval of bevacizumab in mCRC. He has published over 100 articles in peer-reviewed journals such as the New England Journal of Medicine (senior author) and Journal of Clinical Oncology (lead author). Dr. Kabbinavar holds BSc, MBBS and MD degrees from Nagpur University, India, and completed multiple fellowships in&#160;UCLA's&#160;Division of Hematology&#47;Oncology, as well as an internship and residency at Harvard University&#8217;s Beth Israel Deaconess Medical Center in Boston. </font></div><div><font><br></font></div><div style="margin-bottom:0.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In connection with Dr. Kabbinavar joining Cardiff Oncology, the Company&#8217;s Board of Directors approved the grant of non-qualified stock options to purchase 425,000 shares of Cardiff Oncology common stock outside of the Cardiff Oncology 2021 Omnibus Equity Incentive Plan. The stock option was granted as an inducement material to Dr. Kabbinavar becoming an employee of Cardiff Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). The option was granted as of January 30, 2023, and has an exercise price of $1.75 per share, the closing price on the grant date. The option vests over four years with 25% vesting after 12 months and the remaining shares vesting monthly over the following 36-months, subject to Dr. Kabbinavar&#8217;s continued employment with Cardiff Oncology on such vesting dates.</font></div><div style="height:59.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.637%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.959%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-1-</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.48pt;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">References</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1. H. Hurwitz, L. Fehrenbacher, W. Novotny, T. Cartwright, J. Hainsworth, W. Heim, J. Berlin, A. Baron, S. Griffing, E. Holmgren, N. Ferrara, G. Fyfe, B. Rogers, R. Ross, and F. Kabbinavar&#59; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Bevacizumab Plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#59; The New England Journal of Medicine, Vol. 350, Jun 3, 2004, pp. 2335-2342</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2. Fairooz F. Kabbinavar, Joseph Schulz, Michael McCleod, Taral Patel, John T. Hamm, J. Randolph Hecht,</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Robert Mass, Brent Perrou, Betty Nelson, and William F. Novotny&#59; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Addition of Bevacizumab to Bolus Fluorouracil and Leucovorin in First-Line Metastatic Colorectal Cancer&#58; Results of a Randomized Phase II Trial&#59; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Journal of Clinical Oncology, Vol. 23, Jun 1, 2005, pp. 3697-3705</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">About Cardiff Oncology, Inc.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. The Company&#8217;s lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard-of-care (SoC) therapeutics in clinical programs targeting indications such as KRAS&#47;NRAS-mutated metastatic colorectal cancer (mCRC) and metastatic pancreatic ductal adenocarcinoma (mPDAC), as well as in investigator-initiated trials in triple negative breast cancer (TNBC) and small cell lung cancer (SCLC). These programs and the Company&#8217;s broader development strategy is designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone. For more information, please visit&#160;</font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">https&#58;&#47;&#47;www.cardiffoncology.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Forward Looking Statements</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as &#34;anticipate,&#34; &#34;believe,&#34; &#34;forecast,&#34; &#34;estimated&#34; and &#34;intend&#34; or other similar terms or expressions that concern Cardiff Oncology's expectations, strategy, plans or intentions. These forward-looking statements are based on Cardiff Oncology's current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results&#59; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidate&#59; risks related to business interruptions, including the outbreak of COVID-19 coronavirus, which could seriously harm our financial condition and increase our costs and expenses&#59; uncertainties of government or third party payer reimbursement&#59; dependence on key personnel&#59; limited experience in marketing and sales&#59; substantial competition&#59; uncertainties of patent protection and litigation&#59; dependence upon third parties&#59; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. There are no guarantees that our product candidate will be utilized or prove to be commercially successful. Additionally, there are no guarantees that future clinical trials will be completed or successful or that any precision medicine therapeutics will receive regulatory approval for any indication or prove to be commercially successful. Investors should read the risk factors set forth in Cardiff Oncology's Form 10-K for the year ended&#160;December 31, 2021, and other periodic reports filed with the Securities and Exchange Commission. While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Forward-looking statements included herein are made as of the date hereof, and Cardiff Oncology does not undertake any obligation to update publicly such statements to reflect subsequent events or circumstances.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Cardiff Oncology Contact&#58; </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">James Levine</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Chief Financial Officer </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">858-952-7670 </font></div><div><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">jlevine&#64;cardiffoncology.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">   </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Investor Contact&#58; </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Joyce Allaire </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">LifeSci Advisors </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">212-915-2569 </font></div><div><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">jallaire&#64;lifesciadvisors.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div><div style="height:59.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.637%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.959%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-2-</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>crdf-20230202.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:3c326e01-e1b2-4e6a-a928-18813257a8d6,g:6855d6d1-d8b6-4076-938e-4db32b3319c3-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:crdf="http://www.cardiffoncology.com/20230202" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.cardiffoncology.com/20230202">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="crdf-20230202_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="crdf-20230202_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.cardiffoncology.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>crdf-20230202_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:3c326e01-e1b2-4e6a-a928-18813257a8d6,g:6855d6d1-d8b6-4076-938e-4db32b3319c3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityCentralIndexKey_56c7dd96-0327-4c81-aa92-45c855ac1c65_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_a30694c5-5c33-4c2e-b48b-70fc746bb2c4_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_9d4d4e9a-f168-4546-aa9c-aad352524209_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_4b5f005d-a919-4d15-9ad6-00f416761f3c_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_c5a303cf-634c-455f-9df0-e56a4d566159_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_60183bd8-494e-4151-a5fa-4e77713a9d87_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_67009fb6-3539-416e-9a5b-ff4bcc67b3ef_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_7f773a23-914d-4bc1-a783-ff8aeb3ab9bb_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_739617fe-6c33-4fb4-8a3e-576902eb6a4f_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_edef13a6-8d1a-48b3-9222-07b6f9ca0335_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_1fe376b3-fe97-4c7f-9b1e-204be8b076b2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_6c8a15ee-4417-4b84-bbc9-e3ce4e75b827_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_5249a416-5076-4d5c-a9d9-591c1bf02cbd_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_63b27d3f-5bf6-4cee-9bd8-decb72701871_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_d09f5aa4-05f9-49fc-a3b1-82a85d792b07_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_663ef3b1-7bf5-4c5a-bc2a-8058b445bbb1_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_3ac7f444-003a-41e8-89e6-cec16f1dd7b3_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_437f4923-5f20-466b-84da-ae7ea88f0ff0_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_f03d5f46-7255-45f7-a75d-2e3b6ba4beb0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_402ecd92-ca50-40ab-bd49-474d1ac29acc_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_89e990f2-12f5-41ea-be5c-a46324267dee_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>crdf-20230202_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:3c326e01-e1b2-4e6a-a928-18813257a8d6,g:6855d6d1-d8b6-4076-938e-4db32b3319c3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/Cover" xlink:type="simple" xlink:href="crdf-20230202.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_f36bdf38-2330-4fed-a555-110db70440a4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_b1009d87-5235-4d62-8aca-cdcc20fde21c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f36bdf38-2330-4fed-a555-110db70440a4" xlink:to="loc_dei_DocumentType_b1009d87-5235-4d62-8aca-cdcc20fde21c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_74c9192a-c9e3-448f-b997-8bfa727fedf2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f36bdf38-2330-4fed-a555-110db70440a4" xlink:to="loc_dei_DocumentPeriodEndDate_74c9192a-c9e3-448f-b997-8bfa727fedf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_92fa329d-425e-44f4-9b0f-142597daaae3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f36bdf38-2330-4fed-a555-110db70440a4" xlink:to="loc_dei_EntityRegistrantName_92fa329d-425e-44f4-9b0f-142597daaae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_6e30184a-34ed-45e2-aa0b-8420d02adf56" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f36bdf38-2330-4fed-a555-110db70440a4" xlink:to="loc_dei_EntityFileNumber_6e30184a-34ed-45e2-aa0b-8420d02adf56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_15b2767f-d093-4afd-b426-af0cd84a0925" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f36bdf38-2330-4fed-a555-110db70440a4" xlink:to="loc_dei_EntityTaxIdentificationNumber_15b2767f-d093-4afd-b426-af0cd84a0925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_ef2242f4-2b9b-4361-bf45-e8b789ce0832" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f36bdf38-2330-4fed-a555-110db70440a4" xlink:to="loc_dei_EntityAddressAddressLine1_ef2242f4-2b9b-4361-bf45-e8b789ce0832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_7dc8fc2e-c60b-420f-80fb-911a30b57bc9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f36bdf38-2330-4fed-a555-110db70440a4" xlink:to="loc_dei_EntityAddressStateOrProvince_7dc8fc2e-c60b-420f-80fb-911a30b57bc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_f12279e1-8f94-47ac-a456-61f5b5db4027" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f36bdf38-2330-4fed-a555-110db70440a4" xlink:to="loc_dei_EntityAddressPostalZipCode_f12279e1-8f94-47ac-a456-61f5b5db4027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_c6c48cb4-3ec1-435d-96a3-2b0a99cdfa0e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f36bdf38-2330-4fed-a555-110db70440a4" xlink:to="loc_dei_EntityAddressCityOrTown_c6c48cb4-3ec1-435d-96a3-2b0a99cdfa0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_43daaa4c-fbbb-475a-85d0-32b5b6fb9608" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f36bdf38-2330-4fed-a555-110db70440a4" xlink:to="loc_dei_CityAreaCode_43daaa4c-fbbb-475a-85d0-32b5b6fb9608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_bed38238-8532-42b0-86ea-c675dc9a5ebb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f36bdf38-2330-4fed-a555-110db70440a4" xlink:to="loc_dei_LocalPhoneNumber_bed38238-8532-42b0-86ea-c675dc9a5ebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_5e6f8d46-4ba7-4d76-b136-5addfec8d6a8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f36bdf38-2330-4fed-a555-110db70440a4" xlink:to="loc_dei_Security12bTitle_5e6f8d46-4ba7-4d76-b136-5addfec8d6a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_59e0644a-62df-4302-9f6c-fdd7decc93e0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f36bdf38-2330-4fed-a555-110db70440a4" xlink:to="loc_dei_TradingSymbol_59e0644a-62df-4302-9f6c-fdd7decc93e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_a4766eba-92ba-4a2d-8ede-e615ed5827ab" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f36bdf38-2330-4fed-a555-110db70440a4" xlink:to="loc_dei_WrittenCommunications_a4766eba-92ba-4a2d-8ede-e615ed5827ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_81cb407e-39aa-4cb7-a5c0-ed31847e7ae1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f36bdf38-2330-4fed-a555-110db70440a4" xlink:to="loc_dei_SolicitingMaterial_81cb407e-39aa-4cb7-a5c0-ed31847e7ae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_9c794083-71dd-484e-a29d-c991e3e53aa3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f36bdf38-2330-4fed-a555-110db70440a4" xlink:to="loc_dei_PreCommencementTenderOffer_9c794083-71dd-484e-a29d-c991e3e53aa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_78033964-e6b3-46b0-8dd3-562748f222a8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f36bdf38-2330-4fed-a555-110db70440a4" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_78033964-e6b3-46b0-8dd3-562748f222a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_54e9acda-735e-46e9-82ac-3df961cae759" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f36bdf38-2330-4fed-a555-110db70440a4" xlink:to="loc_dei_EntityEmergingGrowthCompany_54e9acda-735e-46e9-82ac-3df961cae759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_4e2318d0-d674-41e4-916d-e7f86fed107c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f36bdf38-2330-4fed-a555-110db70440a4" xlink:to="loc_dei_EntityIncorporationStateCountryCode_4e2318d0-d674-41e4-916d-e7f86fed107c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_ac9f4878-d410-48e8-bd1b-958f91550992" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f36bdf38-2330-4fed-a555-110db70440a4" xlink:to="loc_dei_EntityCentralIndexKey_ac9f4878-d410-48e8-bd1b-958f91550992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_f8754ac1-502c-4a86-95c9-a4e040b8f2cf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f36bdf38-2330-4fed-a555-110db70440a4" xlink:to="loc_dei_AmendmentFlag_f8754ac1-502c-4a86-95c9-a4e040b8f2cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>crdf-20230202_g1.jpg
<TEXT>
begin 644 crdf-20230202_g1.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  N *8# 2(  A$! Q$!_\0
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M4BI0=TSCE%Q;C)6:"BBBK)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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@MSW-[/"FQ9KF1B\K@=EW'"CLJJ.U=C110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_0.jpg
<TEXT>
begin 644 image_0.jpg
MB5!.1PT*&@H    -24A$4@  "#P   )$" (   !_LS'E    "7!(67,  40P
M  !9,@$<[ &S  !$8$E$051XG.S<08X<R](FUMZAH)D$S;277HF@#6A56H#F
M)1#W@H^/+&9%97BX?69^#G+4X*LP,_>(C/3OO_T_/@        +\C^H"
M    ?A!:        $806      ! !*$%       006@!      !$$%H
M   1A!8      $ $H04      !!!: $      $006@       !&$%@
M0 2A!0      $$%H 0      1!!:        $806      ! !*$%       0
M06@!      !$$%H        1A!8      $ $H04      !!!: $      $00
M6@       !&$%@      0 2A!0      $$%H 0      1!!:        $806
M      ! !*$%       006@!      !$$%H        1A!8      $ $H04
M     !!!: $      $006@       !&$%@      0 2A!0      $$%H 0
M    1!!:        $806      ! !*$%       006@!      !$$%H
M   1A!8      $ $H04      !!!: $      $006@       !&$%@
M0 2A!0      $$%H 0      1!!:        $806      ! !*$%       0
M06@!      !$$%H        1A!8      $ $H04      !!!: $      $00
M6@       !&$%@      0 2A!0      $$%H 0      1!!:        $806
M      ! !*$%       006@!      !$$%H        1A!8      $ $H04
M     !!!: $      $006@       !&$%@      0 2A!0      $$%H 0
M    1!!:        $806      ! !*$%       006@!      !$$%H
M   1A!8      $ $H04      !!!: $      $006@       !&$%@
M0 2A!0      $$%H 0      1!!:        $806      ! !*$%       0
M06@!      !$$%H        1A!8      $ $H04      !!!: $      $00
M6@       !&$%@      0 2A!0      $$%H 0      1!!:        $806
M      ! !*$%       006A!L?_W?_Z?5S[590(     \#BA!04N!A4R#
M  " HP@MV.=^5B&]       83&C!#D_$%:(+     (!AA!8\Z^FX0G0!
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MEL'G^X-; P     XA-#B%"5G^IN/]4_H$0    !@,*'%$8XZRC^J60    "
M2806PQU[@G]LXP      ?0DMQG)J_V$(      "M""T&*CFICSVL-PT
M@"Z$%M,XH/^4L0      Y!-:S.%<_DM&!     "03&@Q@;/XZTIFU7=<
M   ["2UZ<P3_'G,#      @DM&C,L?M-!@@     $$5HT9+3]H4,$P     @
MA-"B&2?L3RB9Z@F#!0    #X%J%%)P[6'V6\      "UA!8].$_?QIP!
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M     %PDM*CG4'L\2PP     <(70HI[C[!-890    " +PDMZCG+/H2%!@
M  !X36A1S/\!_CDL-     # :T*+8@ZRCV*Y 0    !>$%H4<X1]%*$%
M , +0HMBCK!/8\4!     /Y&:%',$?9IK#@     P-\(+8HYOSZ01?_I__M_
M_M?7G^H" 0   ("MA!:5_!_=G\FB?YE52"\     X$Q"BTI"BS,=N^AO9!6B
M"P     XBM"BDM#B3&>N^_W$0G0!     .,)+2J=>7C-:>N^,*X070    #
M;$*+2J<=7O./<];]H;A"= $     4PDM*IUS>,VO3ECW#7&%W (     YA%:
M5#KA\)H_C5_WG8F%Z (     )A%:5!I_>,VG!J][25PAN@    " ,806E08?
M7O/"R'4OCRM$%P     P@-"BTLC#:[XT;]W+4PJY!0    #,(+2H-._PFBLF
MK7MY."&Z     (!)A!:5)AU><]V,=2\/)$07     #"/T*+2C,-KOJO[NI>'
M$*(+     )A*:%&I^^$U[VF][N79@]P"      836E1J?7C-VYJN>WGD(+H
M    @/&$%I6:'EYS4[MU+X\91!<     < BA1:5VA]<LT6C=RZ,%T04
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M      XAM*@DM#C3U-#B?FU+C&\0      836E026IRI<-T/.= _I$T
MF$=H44EH<:9AH<62F3SAJ&8!    8 :A126AQ9FJUOW,$_PSNP8   " IH06
ME8069QH06JP:Q38G]PX     C0@M*@DMSM0]M%@UA\T.;Q\     6A!:5!):
MG*EO:+%J H4, 0    "2"2TJ"2W.5++N3NI_91H     D$EH44EH<2:A13G3
M     (!,0HM*0HLSM0LM%O:>PT      ()#0HI+0XDQ"BP0& @    "!A!:5
MA!9G$EHD,!      ""2TJ"2T.)/0(H&!     $ @H44EH<69A!8)# 0
M @DM*@DMSB2T2& @     !!(:%%):'$FH44" P$   " 0$*+2D*+,PDM$A@(
M      026E026IQ):)' 0      @D-"BDM#B3$*+! 8"     (&$%I6$%F<2
M6B0P$      ()+2H)+0XD] B@8$     0""A126AQ9F$%@D,!      ""2TJ
M"2W.)+1(8"      $$AH44EH<2:A10(# 0   (! 0HM*0HLS"2T2& @
M!!):5!):G$EHD<!      ""0T**2T.),0HL$!@(     @806E8069Q):)# 0
M      @DM*@DM#B3T"*!@0    ! (*%%):'%F806"0P$      ()+2H)+<XD
MM$A@(      02&A126AQ)J%% @,!    @$!"BTI"BS,)+1(8"      $$EI4
M$EJ<26B1P$      ()#0HI+0XDQ"BP0& @    "!A!:5A!9G$EHD,!
M""2TJ"2T.)/0(H&!     $ @H44EH<69A!8)# 0      @DM*@DMSB2T2& @
M     !!(:%%):'$FH44" P$   " 0$*+2D*+,PDM$A@(      026E026IRI
M9-&=T?_&0      @D-"BDM#B3$*+! 8"     (&$%L6$%J>I2JJ<T?_&0
M   @D-"BF/_8XC1"BQ & @    "!A!;%A!:G$5J$,!      ""2T*';G"%MN
MT4[A<CNC_XV!     $ @H44QH<51A!8Y# 0      @DMBMT\Q99;-%*[T,[H
M?V,@     !!(:%%/:'$(H46..],8.1      ""&TJ.<_MCA!^2H[IO^5:0
M  ! )J%%O?O'V7*+<"'K>_.D?L9AO2$     0#*A102YQ6 YBWO_O+[[J?WA
M[0,   ! /J%%A"7GVJ*+-&G+NBJTZ'AP?W+O     -"(T")%V@$W-P4NZ,*#
M^T;']V=V#0    !-"2U2+#SC%EW42E[*Y2?XR8?X1S4+     #,(+8(L/^P6
M76R6OX)/G.-G'N6?TRD     3"*T"/+$D;?<8H^'UNZ)Y7OH-#_G0']\@P
M   PF- B2Z.S;W[JM6K/G>F7G^P/;@T     #B&TR/+<\;?HX@E-%^OIP_W]
MY_OS.@(   " ,PDMXCR=6X@NEFB]3!N.^'>>\@]K!P    !.)K1(U/I ?+P-
MJ[-A@?8<]#]]UC^C"P    #@)Z%%J!DGX_-,6I=M)_Y/'/JW+AX     ^!NA
M1:X]Y^.BBXM&+L?.H_]5I_\=:P8     +A):Y-IV2BZZ>&WV*O3* 'I5"P
M  !\E] BFMRBW E+L#D)>"\,:%$D     '"3T"+=YD-ST<5/1XU]?R1P/15(
MK@T     6$MHT8/H8J<SIQV8#924)+$     @$)"BS;VGZ2''*;O9,@Y(4%.
M)0    # -D*+3ARI/\IX?RK\3QP*+PT     E!-:].-L?3DC_5-5>""Q
M ("3"2U:*CEDSS]G?X,QOE8>)X@K     . H0HO&'+C?(?BYKCQ:$%<
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MR@\#\BM<8EM<T2NZV%GA;-O.1_S,@"JU=^CXA\.,9^.,+OK:]K5KI8!,GF
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M%KRI/'7H$E=\3$DL1!<YRD\N')1 K)(;;<8M/^,1-Z"%1JKVS(R]"AS+4PB
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MMZ27,=-;ZX2Q5/7H0?&0;3VV&&.+(M^N<VVIY07 >X06\,/]T_:.!^YKG3G
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M9'DOY07<ES#&DN(W-)500]_R+IK118BT.RA3^)0"2WI;52^9*YM@V&02VE'
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M9Y$MQA)>9%I5R;-:4N'F^['<^/DLV0]]VX>_$5I 2[**=IYX$2E\+TFKO[R
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M,=YT0H]PG= "H%+YV]NPE\7R!M_NNG"8L:NY1/GJWQ]@[=*$;X_P\BZ:T<4
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MT04 D.F]-XT6+QM]^^I;.>PGM   H),9/_9F= $ 9)H:6O3MJVG94$5H 0!
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MH04  %3R,Q4 >-J>V*#P4SW@_QC0 I036@    # <.6YPOBXXA\SNH!:0@L
M    F*\\8)!8=&D$:@DM     . (Y3'#X,3BPW]F 8L(+0    #@%.5AP\BX
MXL-_9@'K""T     X"SEP<.\(_YA[4 AH04     '*<\?IATOC^O(R@DM
M  " 0Y5'$0,.]Z?V!56$%@    !PNO)DHN^9_NSN8#^A!0    #P0WE0T>Y
M?W9W4$)H 0    #\%T'%12?T")L)+0    " OQ)4 #L)+0    " JT04P*.$
M%@      0 2A!0      $$%H 0      1!!:        $806      ! !*$%
M       006@!      !$$%H        1A!8      $ $H04      !!!: $
M     $006@       !&$%@      0 2A!0      $$%H 0      1!!:
M    $806      ! !*$%       006@!      !$$%H        1A!8
M $ $H04      !!!: $      $006@       !&$%@      0 2A!0
M$$%H 0      1!!:        $806      ! !*$%       006@!      !$
M$%H        1A!8      $ $H04      !!!: $      $006@       !&$
M%@      0 2A!0      $$%H 0      1!!:        $806      ! !*$%
M       006@!      !$$%H        1A!8      $ $H04      !!!: $
M     $006@       !&$%@      0 2A!0      $$%H 0      1!!:
M    $806      ! !*$%       006@!      !$$%H        1A!8
M $ $H04      !!!: $      $006@       !&$%@      0 2A!0
M$$%H 0      1!!:    _SG ZG\   %.241!5'][=BP     ,,C?>AH[2B,
M ( %:0$      "Q("P      8$%:        "]("      !8D!8      ,""
MM        !:D!0      L" M      " !6D!       L2 L      &!!6@
M      O2 @      6) 6      # @K0        6I 4      + @+0
M@ 5I 0      +$@+      !@05H        +T@(      %B0%@      P(*T
M        %J0%      "P("T      ( %:0$      "Q("P      8$%:
M    "]("      !8D!8      ,""M        !:D!0      L" M      "
M!6D!       L2 L      &!!6@        O2 @      6) 6      # 0NM#
2.\@.1)+U     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140556947599616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Feb. 02, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb.  02,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Cardiff Oncology,&#160;Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35558<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-2004382<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">11055 Flintkote Avenue<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(858)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">952-7570<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CRDF<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001213037<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>crdf-20230202_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="crdf-20230202.xsd" xlink:type="simple"/>
    <context id="i1cb9060bc1554995858a89144c9522d0_D20230202-20230202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <startDate>2023-02-02</startDate>
            <endDate>2023-02-02</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="i1cb9060bc1554995858a89144c9522d0_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3YmNmOTNiNjQ4ZTQ3Mzg5N2JkODY4ZTU3M2I4MDRiL3NlYzoxN2JjZjkzYjY0OGU0NzM4OTdiZDg2OGU1NzNiODA0Yl80L2ZyYWc6OTEyNTFjMzQyOGIxNDFkMGFiMzJmZjhlN2NiNTBjNWQvdGFibGU6NjM5Zjk0NmVlYmUxNDZmY2FkM2FiYTAyNDJkYTUxMzkvdGFibGVyYW5nZTo2MzlmOTQ2ZWViZTE0NmZjYWQzYWJhMDI0MmRhNTEzOV8yLTEtMS0xLTQzMDQz_f6a2203c-6f6b-481c-92d3-25686258c4c5">0001213037</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i1cb9060bc1554995858a89144c9522d0_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3YmNmOTNiNjQ4ZTQ3Mzg5N2JkODY4ZTU3M2I4MDRiL3NlYzoxN2JjZjkzYjY0OGU0NzM4OTdiZDg2OGU1NzNiODA0Yl80L2ZyYWc6OTEyNTFjMzQyOGIxNDFkMGFiMzJmZjhlN2NiNTBjNWQvdGFibGU6NjM5Zjk0NmVlYmUxNDZmY2FkM2FiYTAyNDJkYTUxMzkvdGFibGVyYW5nZTo2MzlmOTQ2ZWViZTE0NmZjYWQzYWJhMDI0MmRhNTEzOV8zLTEtMS0xLTQzMDQz_f099ed71-137b-4ba9-80db-f87a5f3cdf19">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i1cb9060bc1554995858a89144c9522d0_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3YmNmOTNiNjQ4ZTQ3Mzg5N2JkODY4ZTU3M2I4MDRiL3NlYzoxN2JjZjkzYjY0OGU0NzM4OTdiZDg2OGU1NzNiODA0Yl8xL2ZyYWc6YTZlODlmMzYxOTllNDViNjgzYTg2ODE2YzZjYTAwNTAvdGV4dHJlZ2lvbjphNmU4OWYzNjE5OWU0NWI2ODNhODY4MTZjNmNhMDA1MF8yNTIy_fcd555e7-1505-41a4-aa29-8aeec969eac0">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i1cb9060bc1554995858a89144c9522d0_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3YmNmOTNiNjQ4ZTQ3Mzg5N2JkODY4ZTU3M2I4MDRiL3NlYzoxN2JjZjkzYjY0OGU0NzM4OTdiZDg2OGU1NzNiODA0Yl8xL2ZyYWc6YTZlODlmMzYxOTllNDViNjgzYTg2ODE2YzZjYTAwNTAvdGV4dHJlZ2lvbjphNmU4OWYzNjE5OWU0NWI2ODNhODY4MTZjNmNhMDA1MF8yMjg_ca52523a-d630-405e-9cb7-4e4a12d69383">2023-02-02</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i1cb9060bc1554995858a89144c9522d0_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3YmNmOTNiNjQ4ZTQ3Mzg5N2JkODY4ZTU3M2I4MDRiL3NlYzoxN2JjZjkzYjY0OGU0NzM4OTdiZDg2OGU1NzNiODA0Yl8xL2ZyYWc6YTZlODlmMzYxOTllNDViNjgzYTg2ODE2YzZjYTAwNTAvdGV4dHJlZ2lvbjphNmU4OWYzNjE5OWU0NWI2ODNhODY4MTZjNmNhMDA1MF8yNTMy_d0032a91-afa4-4f8a-9bdf-5d185f128d4f">Cardiff Oncology,&#160;Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i1cb9060bc1554995858a89144c9522d0_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3YmNmOTNiNjQ4ZTQ3Mzg5N2JkODY4ZTU3M2I4MDRiL3NlYzoxN2JjZjkzYjY0OGU0NzM4OTdiZDg2OGU1NzNiODA0Yl8xL2ZyYWc6YTZlODlmMzYxOTllNDViNjgzYTg2ODE2YzZjYTAwNTAvdGFibGU6M2VlZWUxZTIxNjQ5NDFlNGI5ZWVjYjVhNjY2NDZkZGQvdGFibGVyYW5nZTozZWVlZTFlMjE2NDk0MWU0YjllZWNiNWE2NjY0NmRkZF8wLTAtMS0xLTQzMDQz_00ab37c4-b23c-433e-91bf-4bd1b757bf28">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="i1cb9060bc1554995858a89144c9522d0_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3YmNmOTNiNjQ4ZTQ3Mzg5N2JkODY4ZTU3M2I4MDRiL3NlYzoxN2JjZjkzYjY0OGU0NzM4OTdiZDg2OGU1NzNiODA0Yl8xL2ZyYWc6YTZlODlmMzYxOTllNDViNjgzYTg2ODE2YzZjYTAwNTAvdGFibGU6M2VlZWUxZTIxNjQ5NDFlNGI5ZWVjYjVhNjY2NDZkZGQvdGFibGVyYW5nZTozZWVlZTFlMjE2NDk0MWU0YjllZWNiNWE2NjY0NmRkZF8wLTEtMS0xLTQzMDQz_b4d24b9c-c600-4a35-b316-305c7c0cd54c">001-35558</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i1cb9060bc1554995858a89144c9522d0_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3YmNmOTNiNjQ4ZTQ3Mzg5N2JkODY4ZTU3M2I4MDRiL3NlYzoxN2JjZjkzYjY0OGU0NzM4OTdiZDg2OGU1NzNiODA0Yl8xL2ZyYWc6YTZlODlmMzYxOTllNDViNjgzYTg2ODE2YzZjYTAwNTAvdGFibGU6M2VlZWUxZTIxNjQ5NDFlNGI5ZWVjYjVhNjY2NDZkZGQvdGFibGVyYW5nZTozZWVlZTFlMjE2NDk0MWU0YjllZWNiNWE2NjY0NmRkZF8wLTItMS0xLTQzMDQz_4fc2485d-48f3-499c-afac-a34522ae4013">27-2004382</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i1cb9060bc1554995858a89144c9522d0_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3YmNmOTNiNjQ4ZTQ3Mzg5N2JkODY4ZTU3M2I4MDRiL3NlYzoxN2JjZjkzYjY0OGU0NzM4OTdiZDg2OGU1NzNiODA0Yl8xL2ZyYWc6YTZlODlmMzYxOTllNDViNjgzYTg2ODE2YzZjYTAwNTAvdGV4dHJlZ2lvbjphNmU4OWYzNjE5OWU0NWI2ODNhODY4MTZjNmNhMDA1MF8yNTI5_c5ed254f-2e6a-4de2-88e7-ce5f6e0af877">11055 Flintkote Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i1cb9060bc1554995858a89144c9522d0_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3YmNmOTNiNjQ4ZTQ3Mzg5N2JkODY4ZTU3M2I4MDRiL3NlYzoxN2JjZjkzYjY0OGU0NzM4OTdiZDg2OGU1NzNiODA0Yl8xL2ZyYWc6YTZlODlmMzYxOTllNDViNjgzYTg2ODE2YzZjYTAwNTAvdGV4dHJlZ2lvbjphNmU4OWYzNjE5OWU0NWI2ODNhODY4MTZjNmNhMDA1MF8yNTMz_0e52a425-00e4-4666-880b-684289613643">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i1cb9060bc1554995858a89144c9522d0_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3YmNmOTNiNjQ4ZTQ3Mzg5N2JkODY4ZTU3M2I4MDRiL3NlYzoxN2JjZjkzYjY0OGU0NzM4OTdiZDg2OGU1NzNiODA0Yl8xL2ZyYWc6YTZlODlmMzYxOTllNDViNjgzYTg2ODE2YzZjYTAwNTAvdGV4dHJlZ2lvbjphNmU4OWYzNjE5OWU0NWI2ODNhODY4MTZjNmNhMDA1MF8yNTM0_ca4e5cf3-445f-4c66-ac70-c80a9e64ffaa">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i1cb9060bc1554995858a89144c9522d0_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3YmNmOTNiNjQ4ZTQ3Mzg5N2JkODY4ZTU3M2I4MDRiL3NlYzoxN2JjZjkzYjY0OGU0NzM4OTdiZDg2OGU1NzNiODA0Yl8xL2ZyYWc6YTZlODlmMzYxOTllNDViNjgzYTg2ODE2YzZjYTAwNTAvdGV4dHJlZ2lvbjphNmU4OWYzNjE5OWU0NWI2ODNhODY4MTZjNmNhMDA1MF8yNTMw_99c6815e-685e-40ff-a3f3-b5bc4dd77aa6">92121</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i1cb9060bc1554995858a89144c9522d0_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3YmNmOTNiNjQ4ZTQ3Mzg5N2JkODY4ZTU3M2I4MDRiL3NlYzoxN2JjZjkzYjY0OGU0NzM4OTdiZDg2OGU1NzNiODA0Yl8xL2ZyYWc6YTZlODlmMzYxOTllNDViNjgzYTg2ODE2YzZjYTAwNTAvdGV4dHJlZ2lvbjphNmU4OWYzNjE5OWU0NWI2ODNhODY4MTZjNmNhMDA1MF8yNTI1_27532444-c844-47e7-84c1-f108c7d710f6">(858)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i1cb9060bc1554995858a89144c9522d0_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3YmNmOTNiNjQ4ZTQ3Mzg5N2JkODY4ZTU3M2I4MDRiL3NlYzoxN2JjZjkzYjY0OGU0NzM4OTdiZDg2OGU1NzNiODA0Yl8xL2ZyYWc6YTZlODlmMzYxOTllNDViNjgzYTg2ODE2YzZjYTAwNTAvdGV4dHJlZ2lvbjphNmU4OWYzNjE5OWU0NWI2ODNhODY4MTZjNmNhMDA1MF8yNTM1_e0e91766-ad20-4df8-95aa-ced02b04f81a">952-7570</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i1cb9060bc1554995858a89144c9522d0_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3YmNmOTNiNjQ4ZTQ3Mzg5N2JkODY4ZTU3M2I4MDRiL3NlYzoxN2JjZjkzYjY0OGU0NzM4OTdiZDg2OGU1NzNiODA0Yl8xL2ZyYWc6YTZlODlmMzYxOTllNDViNjgzYTg2ODE2YzZjYTAwNTAvdGFibGU6NTYxMGNjMGZlMjUxNDc1NGFhYmViMDg3MzI3NjFjYWQvdGFibGVyYW5nZTo1NjEwY2MwZmUyNTE0NzU0YWFiZWIwODczMjc2MWNhZF8xLTAtMS0xLTQzMDQz_31731655-7ed4-4328-a044-25c207d7bd79">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i1cb9060bc1554995858a89144c9522d0_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3YmNmOTNiNjQ4ZTQ3Mzg5N2JkODY4ZTU3M2I4MDRiL3NlYzoxN2JjZjkzYjY0OGU0NzM4OTdiZDg2OGU1NzNiODA0Yl8xL2ZyYWc6YTZlODlmMzYxOTllNDViNjgzYTg2ODE2YzZjYTAwNTAvdGFibGU6NTYxMGNjMGZlMjUxNDc1NGFhYmViMDg3MzI3NjFjYWQvdGFibGVyYW5nZTo1NjEwY2MwZmUyNTE0NzU0YWFiZWIwODczMjc2MWNhZF8xLTItMS0xLTQzMDQz_9592acb5-9ba7-46b9-914b-1d0666117f8b">CRDF</dei:TradingSymbol>
    <dei:WrittenCommunications
      contextRef="i1cb9060bc1554995858a89144c9522d0_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3YmNmOTNiNjQ4ZTQ3Mzg5N2JkODY4ZTU3M2I4MDRiL3NlYzoxN2JjZjkzYjY0OGU0NzM4OTdiZDg2OGU1NzNiODA0Yl8xL2ZyYWc6YTZlODlmMzYxOTllNDViNjgzYTg2ODE2YzZjYTAwNTAvdGV4dHJlZ2lvbjphNmU4OWYzNjE5OWU0NWI2ODNhODY4MTZjNmNhMDA1MF8yNTM2_d7aa97c3-f2b9-4105-9ef4-23e53732000a">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="i1cb9060bc1554995858a89144c9522d0_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3YmNmOTNiNjQ4ZTQ3Mzg5N2JkODY4ZTU3M2I4MDRiL3NlYzoxN2JjZjkzYjY0OGU0NzM4OTdiZDg2OGU1NzNiODA0Yl8xL2ZyYWc6YTZlODlmMzYxOTllNDViNjgzYTg2ODE2YzZjYTAwNTAvdGV4dHJlZ2lvbjphNmU4OWYzNjE5OWU0NWI2ODNhODY4MTZjNmNhMDA1MF8yNTI2_4e791e3b-04b5-4fa6-86d1-e52f4db9ef95">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="i1cb9060bc1554995858a89144c9522d0_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3YmNmOTNiNjQ4ZTQ3Mzg5N2JkODY4ZTU3M2I4MDRiL3NlYzoxN2JjZjkzYjY0OGU0NzM4OTdiZDg2OGU1NzNiODA0Yl8xL2ZyYWc6YTZlODlmMzYxOTllNDViNjgzYTg2ODE2YzZjYTAwNTAvdGV4dHJlZ2lvbjphNmU4OWYzNjE5OWU0NWI2ODNhODY4MTZjNmNhMDA1MF8yNTIz_2ee45075-1142-4031-98a7-392fb68985cf">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="i1cb9060bc1554995858a89144c9522d0_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3YmNmOTNiNjQ4ZTQ3Mzg5N2JkODY4ZTU3M2I4MDRiL3NlYzoxN2JjZjkzYjY0OGU0NzM4OTdiZDg2OGU1NzNiODA0Yl8xL2ZyYWc6YTZlODlmMzYxOTllNDViNjgzYTg2ODE2YzZjYTAwNTAvdGV4dHJlZ2lvbjphNmU4OWYzNjE5OWU0NWI2ODNhODY4MTZjNmNhMDA1MF8yNTI3_f149c676-f9bf-432a-a330-d3403c4e5530">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany
      contextRef="i1cb9060bc1554995858a89144c9522d0_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3YmNmOTNiNjQ4ZTQ3Mzg5N2JkODY4ZTU3M2I4MDRiL3NlYzoxN2JjZjkzYjY0OGU0NzM4OTdiZDg2OGU1NzNiODA0Yl8xL2ZyYWc6YTZlODlmMzYxOTllNDViNjgzYTg2ODE2YzZjYTAwNTAvdGV4dHJlZ2lvbjphNmU4OWYzNjE5OWU0NWI2ODNhODY4MTZjNmNhMDA1MF8yNTMx_0af40fea-e26e-4308-a798-8195ef04bc50">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
M08!"5DAYFLP:!   V@\  !@   !X;"]W;W)K<VAE971S+W-H965T,2YX;6R5
MEV]OZC84QK^*E4G3O=)M$QM2: =(E):MNO]0Z7:E37MA$@>L)G;F.*5\^QT'
MFC MG- W8"<^3W[V.7EBC[;:/!<;(2QYS5)5C+V-M?F-[Q?11F2\N-2Y4' G
MT2;C%KIF[1>Y$3RN@K+49T%PY6=<*F\RJJXMS&2D2YM*)1:&%&66<;.[%:G>
MCCWJO5UXE.N-=1?\R2CG:[$4]O=\8:#GURJQS(0JI%;$B&3L3>G-+>NY@&K$
M'U)LBZ,V<5-9:?WL.@_QV L<D4A%9)T$A[\7,1-IZI2 XY^#J%<_TP4>M]_4
MY]7D83(K7HB93G_(V&[&WM CL4AXF=I'O?U-'"84.KU(IT7U2[;[L?V^1Z*R
ML#H[! -!)M7^G[\>%N(H ";:'L . :SBWC^HHKSCED]&1F^)<:-!S36JJ5;1
M ">5R\K2&K@K(<Y.9OI%F)%O0<I=\*-#V.T^C)T(FXO5)0G8)\("UOMON \$
M-0:K,5BEU\,PR%_356$-).KO-J*]0K]=P57O39'S2(P]*,]"F!?A37[^B5X%
MOR!\O9JOAZE/[G140BU:\K3+11L<'CZ\^(Q ]&N(_GD0"V&DCLF]B@DDO94'
M5ZK25^6O*X%AS1:BBO?*2KLCCV(M70H!\AO/6LEPG1DWL4P2\EU!9>OU[M,^
MA0\JND0HKVK*JW,HYS(5Y%N9K=I+']<( GK1"\-PB/ ,:I[!.3Q/_)4\Q)!9
MF<B(5VYUF@Y79(,+,.1^;\@0O&&--SP';QK'\$85G]X:Y N,@PRUIA=7I#0(
M0S*'R_996T&F+T*5 D&]KE&OWX6ZM/!B$&W(PN@7J:)65EQR-D6X:- 8;/ N
MLH4N+$_)GS(G,QVW<G4H7C/**,9V9/[T76PSUX-%>]);U0J&RRVY(G=2K#4&
MUWP2*.KHDPIF"EN-T^N$"WP8AL./&$KC_A3W[R\Z@I0M-EIAOM$A<AVRBT$X
M"#"BYE- <0=_DA8\3">$L@^KCV0IHM+ >K5BX4HSG65@.$NKHV<,K?D24-S"
MGPR/I5J3Y2Y;Z;25J.,;\'@WQT@:MZ>X5?^ );%"$3?%4AVLM6@EPH42GA:8
M2]'&\"GNSTN=RDA:MSY?P:&,Y.TKA*MT\C0.3W%#7AAQ$<'R"+#(_09'J!BV
M8M^3Y$21XWJ=9(VA4]Q^_T?V4!0ED'4"XK)=@*PQ=G:6L=]GPJQ=/G\%!;MQ
MQ99SU?HF=@AVHC6^SL[R==@U:9-K4]7]T3=QIDMES>ZDKW:HW]UCD$=;?MR>
M#Y SR*T!=WV M+Z2SZ)]Y7"I #9EC/:"W@ C:^R>X4X]A7J+JYJ;IWS=RH,+
MG,RD?W12<Z?>K]S53D%2D8!0<#D 9S3[@^2^8W5>'=Y6VL)1L&INX/ MC!L
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M J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$%     @ 08!"5I>*NQS
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M4$L! A0#%     @ 08!"5@=!36*!    L0   !               ( !
M &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " !!@$)6*6]=4^T    K @
M$0              @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4
M" !!@$)6F5R<(Q &  "<)P  $P              @ '+ 0  >&PO=&AE;64O
M=&AE;64Q+GAM;%!+ 0(4 Q0    ( $& 0E9(>9K,&@0  -H/   8
M      " @0P(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M" !!@$)6GZ ;\+$"  #B#   #0              @ %<#   >&PO<W1Y;&5S
M+GAM;%!+ 0(4 Q0    ( $& 0E:7BKL<P    !,"   +              "
M 3@/  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( $& 0E:JQ"(6,P$  "("   /
M              "  2$0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !!
M@$)6)!Z;HJT   #X 0  &@              @ &!$0  >&PO7W)E;',O=V]R
M:V)O;VLN>&UL+G)E;'-02P$"% ,4    " !!@$)699!YDAD!  #/ P  $P
M            @ %F$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 )
+ #X"  "P$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>21</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="crdf-20230202.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="crdf-20230202.htm">crdf-20230202.htm</File>
    <File>a101ex020223.htm</File>
    <File>a991ex020223.htm</File>
    <File>crdf-20230202.xsd</File>
    <File>crdf-20230202_lab.xml</File>
    <File>crdf-20230202_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>crdf-20230202_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="21">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "crdf-20230202.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 21
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "crdf-20230202.htm"
     ]
    },
    "labelLink": {
     "local": [
      "crdf-20230202_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "crdf-20230202_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "crdf-20230202.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 22,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 21,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "crdf",
   "nsuri": "http://www.cardiffoncology.com/20230202",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230202.htm",
      "contextRef": "i1cb9060bc1554995858a89144c9522d0_D20230202-20230202",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.cardiffoncology.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230202.htm",
      "contextRef": "i1cb9060bc1554995858a89144c9522d0_D20230202-20230202",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001628280-23-002037-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-23-002037-xbrl.zip
M4$L#!!0    ( $& 0E9>EA@<;#$  /A4 0 0    83$P,65X,#(P,C(S+FAT
M;>U]:9/;1I+V]_=78.77GNX(=*MO71Y'M%KM'<5:LE9JC]>?)HI D2P+!&@<
MI-J_?O.J0N%@'QI9!+GMF+&;( C4D97GDYG?_\>KGR^N?GMW&4S+61*\^^7E
M3Z\O@D=[CQ__>GSQ^/&KJU?!/Z[>_!2<[!\<!E>Y2@M3FBQ5R>/'EV\?!8^F
M93E__OCQ<KG<7Q[O9_GD\=7[Q_BHD\=)EA5Z/R[C1S]\CU?@WUK%/_R_[_]C
M;R]XE4753*=E$.5:E3H.JL*DD^#76!<?@[T]N>LBFU_G9C(M@Z.#H^/@URS_
M:!:*OR]-F>@?['.^?\R?OW],+_E^E,77/WP?FT5@XK\_,OK@]$"=J+/3,QV?
MG.DS=30ZTJ.#>'QRH@^.QN-_'<(@'\/M_)NBO$[TWQ_-3+HWU?C^YT^.YN6+
MI8G+Z?/#@X-O']%]/WP_SM(27I;#C_E/?D;W22J?P,-&65EFL^>'^+!2?RKW
M5&(FZ?,()J#S1_PX^Y,H2[+\^3<'],\+_&9OK&8FN7[^MRLSTT7P5B^#]]E,
MI7\+"]B7O4+G9LPW%N9/S6^ACTN9 SPG,:FV<^*)7+YY]]//O[VY?'L5G/_G
M^\M+_*LYFSO/X_>J*,WXFB^9-(9I/3\^FY=_^<Q.>F=V-35%<#F;)]DUD=KY
M)->:_MHIISKX[ING1T<'+^Q<O_X(>9UB'66YPD/UO((ER_&N1S^XL:YO>(]^
MH!4Z?+$;P#K.5*P#E<8!T2H<6).66:#'8QV59@%?%4$V#K[.:/L)^2N]O'^I
M?M2CO%+Y=?"O?X7,K(9/8Y=N\UX!"QX"H87!Z)J(;*3+I=9I\*,R>9;]&?R7
M&HU,JA8J#X,WK\+@Q_.+=YNPPI]T5.$*#V%Q:6$O5!Z;\3CX.<773Z[#X'4:
M[8>!"E[I1"U5K@.8R%SFL@%+?)'-YBJ]'L("[W^FV/Q*XO^^*_L^N PN@M<!
MZ 7!3\&'+Z@3H#*U)IW@UW]<OK\\_Q &2-A".P$HG2:'=Z! (W4A< <WI%/C
M/OJWCK3<#<(0V);WP!"$8Z!5- TB5>B.D,0[F[SWNV].G[W8L@6&)8BR-,59
M B-9FG)*$Q]GN9YDH.N'WJH64Y4DN*"Y_J,RJ%W ^LYU#C?/ZMOPG!T^>5$$
M,7R$$>/.9"-8!"+=(IB"7D+T&\ +1QJ>.;;+[38&=D#-YWDVSPVL.^]N4<%.
MK7BF&YE.83"15J-$MW9[&S>O1-6YUI>+"C:CT#$M$$MH7!98Q"P/@'?-8)VT
M+HM03@3]2-F? ]'G06%@O"KWK[9D?4T.>-5;X"WCJUMF9;VF<UX8F!_K#'+D
M9E59J02^6^A4X7;C\62F4"IX2NRVV:,9^&U-!FVFBA_F*N=SBF2$IWF<)4FV
M+. 0/OV2AW"-"WJXOT9-:Z[B&)CS7J+'Y?.C)W:A^BGYE1Z;U-A-OP(^4*Q3
M#]L/@BN2,$@1Z$U"SE2 3!GK7&0*T%^;M1&#GRJ@M[+QXYE6*?SWBU/6&MG[
MCMH=#&D=[3_!=1BV;:&J8@BFFQ I4B3)7^&PCE:)1(-@Q^S2]2B;S4Q1R+%4
MP0PT'5!WDD!%Q&''N:IB%-4C_>>?"1\#D-#PFUHU@A^'P7)J0#."XV) D,*R
MT!$"[;=*2CQ)134J2F#M^&C4#] M#'I2#C_J,O,>=;"KV'F2P"F,OI8%4S2[
MWWUS>';PHOOCI4F2<97@/.!-<16583#)LZ((4CV!XZC3"!4^7H/8%-,LU;"?
M./513MHZKFL.1_:^@W5C6STX./PF*FEFH$?B.Z,IL [-#]]!4=CS4MZ $B4G
M;H/=7)R)76$51#FH5KCT)6[R;H@/GR=:?05_'#WQN2F!VT5W(.<4WDSR'XDI
M7^O)"I&4>>TTZ2^E*6''@.^K8*R3#$[93H8+#XL.IZ[,U7ALHKU<)Q2MR,!\
M2PM=[.)BTY&D>]U6R/>PIXLL6>!CY=#5=!=V#ARIR3"=K"J"&; CV-$JG\.X
M8FTI;+&2P&H2QN&D6;I79+ KL#?VT7@-J&>N2Q'9GID#B^$;Q'"W 8T-YYR@
MG52@.1<E%?)OHLRL*H,$YEH*IX K,-M"$W4#X0(M?Q!"/CP%L4.ZGG=EM,M,
MK"&*X:TK3[4<Y>3:'>:2"#W7T<=$%^WYPXZ.#8I;.!$&S_CGS36\]V1/>N95
MFS/-0>'UU^D"+^"XO!^4)<P%R P//M)IL4;'^LW^S:D9F3)XN5XAB6<#MG%G
M]>G8.92OG"P<*Y-4P%;OY&@HFKO=W%]V(NP<R1N\!XMR$\%'*\F1XLC?8&]#
M N-'YD 2.\<'\IA872-1PFB1QK69$[=?YJ8$[@EGN301: !Y-FMYLG!]%#$R
MO%[,=62 <:'80_FARIK9:?%\=);$TJO_8Z)0D$UPU%2.#BXZ9^&*6?HS_%SK
M?6BZ\VA(NO/!T?"59Y";H-\ T0+?*_,L&9@BC12>14"U.:I35G"T5>M (W_^
MXD;@X<'3]5&R&0XEG^R?/<.%P#6/@0^AYY:57MP,H6^V+>P6[B W1OY"?D=@
MQ&"CQ9X,+IA_'A[OQ*QV')[@7[*Q<%,%/!2Y^N6GB$GTG$V"PV?')^P@GK&Q
M,_S@ES^% 1RO730^1NC=*^RZC72J082@>,F6*6SDU,S]G8S1A<3[][Y*M-V[
M>._814J\.;*Z#0([JE*#T79#8 2VV,9F#!(4B"4BB,?IP;<B2M&VS7)M'P@Z
M\(C>N<A(3LZS)88,QDUK4S0 N ::<E6BH4O:;U$3T,Z@:>.?/+L/919]' )M
MW!PF\6%6\XQ!9L_)V@)]K .\LK\2CGM0_T2-P.P!W>:^6"W^]S2W3YZKB=Y#
MF^+C'BEASU6R!(WLT5KP8<.3( ,2(8?[[*OGHYT6U6SFXA *1'T^T7E(WX ]
M'(L)E^LLGZC4_"F?O0!5B2!'UG@]\[T1B/ < \J_W_KA#G>1'[$<\YQD8+RB
M]B&<9IHE<%9=0-@_KH&9S72,QBC\1()LF0@];W3X!+&!-<6F#?Q5)FS2INX3
M\3X:[%TYI##&@L8BU]CM1QH13(;=9@K#,03B%/.#/%79.&QY!Q,.Y!0@6 /T
M=X =1?:$(OYJ\EHTM-AP_T+@#<U5%_O/FF!N\7O6N<W@(S5'_Y5,UG_?2&.L
MNKOLZ)$(&W>RF=:^,>0-0H4"G1?5')4;%8PK7(_8)&2!C50ACCTU,N050!!"
M CL7@*V6: 6R#3VXOV<Y+3I/0E7E%"[\"0_@;<[J"195OC +;Z-V>G9JUR[:
MUNBT V))AT_W#XZ%);'CUO$EC'K".4AT2'N+_P$['CV%L$FQ*:P<(^:%O")?
MS4!JEH9/+0I=MHF<U%]T;N$S#%!K;M"]U6!?ZQT,>6%3H=3P3JSJ#DJ<Y5^U
MJH:N$S8KD,LM4X;LT)GOYP]_+0<C5G&'E=\6WTDTF+.Y$7''5Z80:3  Q9V\
M)7A02S[S<(KA6,+3@:A(D!6(B2(YYQES?:(V=M,*V"PL@WF"3&@^!_(G9!6>
M#9WB*=$N<IAAY 5/J"H(5T?(.92ESFD@:L>VG)9X2*=E SR-_YEE<? >^&B6
M#N&\>#Y&&SWJ"1Y_FN<8MK(.?92?'"NZ,;SO!?-SC2%N$<^K0A=A4 MQ-!1
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MIM2!4*!2)#I@J!$(D<B"ZDS)21J9RF/2' @/"=,B789W(^:53T7,H\-NP40
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M8$AA!)M2/FO7%4('[3 I0LHPL<0X7WNV'1RE]I+7 5%VQ<4/"(!!( !.'Q
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M*L&==Z/"^C'H,YM<V[5U#YW-*]PO>XE_GHW+)7J5J=\ECTXEC6UH0AESBZ]
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M0VX<V2"8BO60-DF#TX&1&7ZK7L,6[X$Q@"&T9$8]*"R1B^ "T31H@LL->7B
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MX9"0*'=?.,_>'<2'/<J"E++*@E<6=]O=CG@_R72$L.CH]Y(*$\C<R.7 G5W
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MWO3UXTT;_O]$P_]/G+?_!5!+ P04    " !!@$)6?"]V:1,9  !;KP  $0
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M7X_@CY&K^TC,[_ 07R*2JQ@3.H\"!T6&$6M,;!XK!P*OR$V7\8.3%F+87DR
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M\UJA $IV-L%SM<7]-(H.7<AU'049BX?^7:CB, J2#\5A(D'_L0D !VIYOI>
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MO7$R#- D1MN5^P*Y<8\OIC>$ #3">!&\,0O4?(I57K\/SCT0";J56]18W&*
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MF X"/I[ZJ!IU5 <@,"C7*85+]-QF=QA.^\//QV04,8KJU+WG,?^R(:;H&/"
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M1:1#N&A%3X_0L=_^P&&DE;.[(:7=;=W#BWED<?;Y.L_6O2<II-)?^PF(!:0
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MK:G^9O$=>2=EQ\'._8%^T[\1?;#S?U!+ 0(4 Q0    ( $& 0E9>EA@<;#$
M /A4 0 0              "  0    !A,3 Q97@P,C R,C,N:'1M4$L! A0#
M%     @ 08!"5G77[#Q=$P  ;D<  !               ( !FC$  &$Y.3%E
M># R,#(R,RYH=&U02P$"% ,4    " !!@$)6?"]V:1,9  !;KP  $0
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M4$L! A0#%     @ 08!"5HG+S=QS!@  WRX  !4              ( !774
L &-R9&8M,C R,S R,#)?<')E+GAM;%!+!08     !P ' ,(!   #?      !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
